Riassunto
In questa sezione sono descritte alcune tecniche chirurgiche spesso utilizzate sugli organi genitali maschili. Questi interventi sono spesso delegati a dei medici inesperti, cosa che può provocare delle invalidità a vita; così, la circoncisione dell’adulto deve essere eseguita con attenzione, al fine di non rimuovere troppa cute della guaina peniena. Gli autori hanno una considerevole esperienza personale delle tecniche descritte e le hanno insegnate. Esistono numerose alternative alle tecniche descritte in questa sezione. Sono descritti i seguenti interventi: circoncisione, protesi peniena, reversione della curvatura peniena, orchidopessi, asportazione di cisti dell’epididimo, idrocele, vasectomia e inversione della vasectomia. Nel Cap. II.4.17 il lettore troverà la descrizione del recupero degli spermatozoi. La lista degli interventi è limitata alle operazioni più spesso effettuate e il lettore potrà riferirsi a un manuale di chirurgia specialistica come il Campbell di urologia per le altre procedure chirurgiche.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Bibliografia
Evans C (1998) The use of penile prostheses in the treatment of impotence. Br J Urol 81:591–598
Lord PH (1964) A bloodless operation for the radical cure of idiopathic hydrocele. Br J Surg 51:914-916
Mulcahy JJ (1991) The management of complications of penile implants. Prob Urol 5:608–627
Bibliografia
Aradhya KW, Best K, Sokal DC (2005) Recent developments in vasectomy. Br Med J 330:296–2999
Labrecque M, Dufresne C, Barone MA, St-Hilaire K (2004) Vasectomy surgical techniques: a systematic review. BMC Med 2:21
Schmidt SS (1987) Vasectomy. Urol Clin North Am 14:149–154
Sokal DC, Irsula B, Hays M, Chen-Mok M, Barone M (2004a) Vasectomy by ligation and excision, with or without fascial interposition: a randomized controlled trial. BMC Med 2:6
Sokal D, Irsula B, Chen-Mok M, Labrecque M, Barone MA (2004b) A comparison of vas occlusion techniques: cautery more effective than ligation and excision with fascial interposition. BMC Urol 4:12
Bibliografia
Belker AM (1980) Microsurgical two-layer vasovasostomy: simplified technique using hinged, folding-approximating clamp. Urology 16:376–381
Belker AM (1988) Infrapubic incisions for specific vasectomy reversal situations. Urology 32:413–415
Belker AM (1995) Microsurgical vasovasostomy: two-layer technique. In: Goldstein M (ed) Surgery of male infertility. Saunders, Philadelphia, pp 61–66
Belker AM (1997) Vasovasostomy. In: Hellstrom WJG (ed) Male infertility and sexual dysfunction. Springer, Berlin Heidelberg New York, pp 230–243
Belker AM, Thomas AJ Jr, Fuchs EF, Konnak JW, Sharlip ID, Thomas AJ Jr (1985) Transient fertility after vasovasostomy in 892 patients. J Urol 134:75–76
Belker AM, Thomas AJ Jr, Fuchs EF, Konnak JW, Sharlip ID, Thomas AJ Jr (1991) Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. J Urol 145:505–511
Berger RE (1998) Triangulation end-to-side vasoepididymostomy. J Urol 159:1951–1953
Hagan KF, Coffey DS (1977) The adverse effects of sperm during vasovasostomy. J Urol 118:269–273
Jarow JP, Sigman M, Buch JP, Oates RD (1995) Delayed appearance of sperm after end-to-side vasoepididymostomy. J Urol 153:1156–1158
Jarow JP, Oates RD, Buch JP, Shaban SF, Sigman M (1997) Epididymovasostomy outcomes based upon level of anastomosis and intraepididymal sperm quality. Assisted Reprod Reviews 7:179–183
Kim ED, Winkel E, Orejuela F, Lipshultz LI (1998) Pathological epididymal obstruction unrelated to vasectomy: results with microsurgical reconstruction. J Urol 160:2078–2080
Kolettis PN, Thomas AJ Jr (1997) Vasoepididymostomy for vasectomy reversal: a critical assessment in the era of intracytoplasmic sperm injection. J Urol 158:467–470
Linnet L (1983) Clinical immunology of vasectomy and vasovasostomy. Urology 22:101–114
Matthews GJ, Schlegel PN, Goldstein M (1995) Patency following microsurgical vasoepididymostomy and vasovasostomy: temporal considerations. J Urol 154:2070–2073
McCallum S, Li PS, Shenykin Y, Su L-M, Chan P, Goldstein M (2002) Comparison of intussusception pull-through and conventional end-to-side microsurgical vasoepididymostomy: prospective randomized controlled study in male Wistar rats. J Urol 167:2284–2288
Myers SA, Mershon CE, Fuchs EF (1997) Vasectomy reversal for treatment of the post-vasectomy pain syndrome. J Urol 157:518–520
Nangia AK, Myles JL, Thomas AJ Jr (2000) Vasectomy reversal for the post-vasectomy pain syndrome: a clinical and histological evaluation. J Urol 164:1939–1942
Niederberger C, Ross LS (1993) Microsurgical epididymovasostomy: predictors of success. J Urol 149:1364–1367
Schmidt SS (1966) Anastomosis of the vas deferens: an experimental study. I. J Urol 75:300–303
Schmidt SS (1978) Vasovasostomy. Urol Clin North Am 5: 585–592
Schoysman R (1990) Vaso-epididymostomy — a survey of techniques and results with considerations of delay of appearance of spermatozoa after surgery. ACTA Eur Fertil 21:239–245
Schoysman R (1993) Clinical situations challenging the established concept of epididymal physiology in the human. ACTA Eur Fertil 24:55–60
Schoysman RJ, Bedford JM (1986) The role of the human epididymis in sperm maturation and sperm storage as reflected in the consequences of epididymovasostomy. Fertil Steril 46:293–299
Silber SJ (1979) Epididymal extravasation following vasectomy as a cause for failure of vasectomy reversal. Fertil Steril 31:309–315
Silber SJ (1988) Pregnancy caused by sperm from vasa efferentia. Fertil Steril 49:373–375
Silber SJ (1989) Apparent fertility of human spermatozoa from the caput epididymis. J Androl 10:263–269
Thomas AJ Jr (1987) Vasoepididymostomy. Urol Clin North Am 14:527–538
Weiske W-H (1994) Pregnancy caused by sperm from vasa efferentia. Fertil Steril 62:642–643
Bibliografia
Comhaire F, Kunnen M (1976) Selective retrograde venography of the internal spermatic vein: a conclusive approach to the diagnosis of varicocele. Andrologia 8:11–24
Comhaire F, Kunnen M (1985) Factors affecting the probability of conception after treatment of subfertile men with varicocele by transcatheter embolization with Bucrylate. Fertil Steril 43:781–786
Gat Y, Bachar GN, Zukerman Z, Belenky A, Gornish M (2004) Varicocele: a bilateral disease. Fertil Steril 81:424–429
Kunnen M (1980) Neue Technik zur Embolisation der Vena spermatica interna: intravenöser Gewebekleber. Fortschr Röntgenstr 133:625–629
Kunnen M (1982) Non-surgical cure of varicocele by transcatheter embolization of the internal spermatic vein with bucrylate. In: Zeitler E, Jecht E (eds) Varicocele and male infertility (Recent Advances in Radiodiagnostic and Therapy). Springer, Berlin Heidelberg New York, pp 153–161
Kunnen M, Comhaire F (1986) Fertility after varicocele embolization with bucrylate. Ann Radiol 29:169–171
Kunnen M, Comhaire F (1991) Non-surgical cure of varicocele by transcatheter embolization of the internal spermatic vein(s) with a tissue adhesive (Histoacryl Transparent). In: Castaneda-Zuniga W (ed) Interventional radiology (Golden Series). Williams and Wilkins, Baltimore, Md., pp 73–101
Bibliografia
Acosta AA, Khalifa E, Oehninger S (1992) Pure human follicle stimulating hormone has a role in the treatment of severe male infertility by assisted reproduction: Norfolk’s total experience. Hum Reprod 7:1067–1072
Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J (2003) Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril 80:914–920
Barwin BH (1982) Mesterolone: a new androgen for the treatment of male infertility. In: Bain J, Schill WB, Schwarzstein L (eds) Treatment of male infertility. Springer, Berlin Heidelberg New York, pp 117–123
Caroppo E, Niederberger C, Vizziello GM, Recombinant human follicle-stimulating hormone as a pretreatment for idiopathic oligoasthenoteratozoospermic patients undergoing intracytoplasmic sperm injection. Fertil Steril 80:1398–1403
Clark RV, Sherins RJ (1989) Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 10:240–247
Comhaire F (1976) Treatment of oligospermia with tamoxifen. Int J Fertil 21:232–238
Comhaire F (1990) Treatment of idiopathic testicular failure with high-dose testosterone undecanoate: a double-blind pilot study. Fertil Steril 54:689–693
Comhaire FH (1992) Conventional treatment of oligo-asthenoteratozoospermia. In: Frick J (ed) Die Anwendung von GnRH und GnRH-Analoga in der Urologie. Blackwell, Vienna, pp 115–123
Comhaire F (2000) Clinical andrology: from evidence-base to ethics. The ‘E’ quintet in clinical andrology. Hum Reprod 15:2067–2071
Dony JM, Smals AG, Rolland R, Fauser BC, Thomas CM (1985) Effect of lower versus higher doses of tamoxifen on pituitary-gonadal function and sperm indices in oligozoospermic men. Andrologia 17:369–378
Foresta C, Bettella A, Merico M, Garolla A, Ferlin A, Rossato M (2002) Use of recombinant human follicle-stimulating hormone in the treatment of male factor infertility. Fertil Steril 77:238–244
Gerris J, Comhaire F, Hellemans P, Peeters K, Schoonjans F (1991) Placebo-controlled trial of high-dose mesterolone treatment of idiopathic male infertility. Fertil Steril 55: 603–607
Heller CG, Rowley MJ, Heller GV (1969) Clomiphene citrate: a correlation of its effect on sperm concentration and morphology, total gonadotropins, ICSH, estrogen and testosterone excretion, and testicular cytology in normal men. J Clin Endocrinol Metab 29:638–649
Horst HJ, Holtje WJ, Dennis M, Coert A, Geelen J, Voigt KD (1976) Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr 54:875–879
Kamischke A, Behre HM, Bergmann M, Simoni M, Schafer T, Nieschlag E (1998) Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum Reprod 13:596–603
Liu PY, Turner L, Rushford D, McDonald J, Baker HW, Conway AJ, Handelsman DJ (1999) Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Hum Reprod 14:1540–1545
Luisi M, Eliasson R, Kicovic PM, Franchi F, Alicicco E (1978) Hypothalamic-pituitary responsiveness to clomiphene stimulation during a placebo controlled study of testosterone undecanoate therapy in normal men. In: Fabbrini A, Steinberger E(eds) Recent progress in andrology. Academic, London, pp 469–475
Ochsenkuhn R, de Kretser DM (2003) The contributions of deficient androgen action in spermatogenic disorders. Int J Androl 26:195–201
Pusch HH (1989) Oral treatment of oligozoospermia with testosteroneundecanoate: results of a double-blind-placebocontrolled trial. Andrologia 21:76–82
Rowe PJ (1988) WHO’s approach to the management of the infertile couple. In: Neglo-Vilar A, Isidori A, Paulson J, Abdelmassih R, de Castro MPP (eds) Andrology and human reproduction. Raven, New York, pp 291–309
Schellen TM, Beek JM (1972) The influence of high doses of mesterolone on the spermiogram. Fertil Steril 23:712–714
Sharpe RM, Millar M, McKinnell C (1993) Relative roles of testosterone and the germ cell complement in determining stage-dependent changes in protein secretion by isolated rat seminiferous tubules. Int J Androl 16:71–81
Skakkebaek NE, Bancroft J, Davidson DW, Warner P (1981) Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 14:49–61
Swerdloff RS, Campfield LA, Palacios A, McClure RD (1979) Suppression of human spermatogenesis by depot androgen: potential for male contraception. J Steroid Biochem 11: 663–670
Vermeulen A, Comhaire F (1978) Hormonal effects of an antiestrogen, tamoxifen, in normal and oligospermic men. Fertil Steril 29:320–327
Vigersky RA, Glass AR (1981) Effects of delta 1-testolactone on the pituitary-testicular axis in oligospermic men. J Clin Endocrinol Metab 52:897–902
Von Mauss J (1974) Ergebnisse der Behandlung von Fertilitätsstörungen des Mannes mit Mesterolon oder einem Placebo. Arzneimittelforschung 24:1338–1442
WHO (1989) Mesterolone and idiopathic male infertility: a double-blind study. World Health Organization Task Force on the Diagnosis and Treatment of Infertility. Int J Androl 12:254–264
WHO (1992) A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. Int J Androl 15: 299–307
Winters SJ, Troen P (1982) Gonadotropin therapy in male infertility. In: Bain J, Schill WB, Schwartzstein L (eds) Treatment of male infertility. Springer, Berlin Heidelberg New York, pp 85–101
Bibliografia
Amory JK, Anawalt BD, Blaskovich PD, Gilchriest J, Nuwayser ES, Matsumoto AM (2002) Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. J Androl 23:84–91
Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM (1999) A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 20:407–414
Anderson RA, Kinniburgh D, Baird DT (2002) Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab 87:3640–3649
Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM (1996) Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 81:757–762
Behre HM, Nashan D, Hubert W, Nieschlag E (1992) Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 74:84–90
Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80:2394–2403
Bouchard P, Garcia E (1987) Influence of testosterone substitution on sperm suppression by LHRH agonists. Hormone Res 28:175–180
Dierich A, Sairam MR, Monaco L, Fimia GM, Gansmuller A, LeMeur M, Sassone-Corsi P (1998) Impairing follicle-stimulating hormone (FSH) signalling in-vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA 95: 13612–13617
Foegh M (1983) Evaluation of steroids as contraceptives in men. Acta Endocr Suppl 260:1–48
Frick J, Danner C, Joos H, Kunit G, Luukkainen T (1981) Spermatogenesis in men treated with subcutaneous application of levonorgestrel and estrone rods. J Androl 2:331–338
Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C (2002) Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 87:3562–3572
Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, Huang ZJ, Zhang GY (2002) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88:562–568
Guerin JF, Rollet J (1988) Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 11:187–199
Handelsman DJ (2006) Male contraception. In: DeGroot LJ (ed) Endocrinology, 5th edn. Saunders, Philadelphia
Handelsman DJ, Conway AJ, Boylan LM (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 71:216–222
Handelsman DJ, Farley TMM, Peregoudov A, Waites GMH, WHO Task Force On Methods For The Regulation Of Male Fertility (1995) Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. Fertil Steril 63:125–133
Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA (1996) Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab 81:4113–4121
Heckel NJ (1939) Production of oligospermia in a man by the use of testosterone propionate. Proc Soc Exp Biol Med 40:658–659
Heller CG, Moore DJ, Paulsen CA, Nelson WO, Laidlaw WM (1959) Effects of progesterone and synthetic progestins on the reproductive physiology of normal men. Fed Proc 18:1057–1064
Kamischke A, Nieschlag E (2004) Progress towards hormonal male contraception. Trends Pharmacol Sci 25:49–57
Kamischke A, Heuermann T, Kruger K, von Eckardstein S, Schellschmidt I, Rubig A, Nieschlag E (2002) An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab 87:530–539
Kumar TR, Wang Y, Lu N, Matzuk MM (1997) FSH is required for ovarian follicle maturation but not for male fertility. Nat Genet 15:201–204
Liu PY, Death AK, Handelsman DJ (2003) Androgens and cardiovascular disease. Endocr Rev 24:313–340
Lobel B, Olivo JF, Guille F, D Le Lanou (1989) Contraception in men: efficacy and immediate toxicity, a study of 18 cases. Acta Urol Belg 57:117–124
Lunn SF, Dixson AF, Sandow J, Fraser HM (1990) Pituitary-testicular function is suppressed by an LHRH antagonist but not by an LHRH agonist in the marmoset monkey. J Endocrinol 125:233–239
Marshall GF, Akhtar FB, Weinbauer GF, Nieschlag E (1986) Gonadotrophin-releasing hormone (GnRH) overcomes GnRH antagonist-induced suppression of LH secretion in primates. J Endocrinol 110:145–150
Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvaia L, Motta R, Pavani A, Capelli M, Flamigni C (1996) A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab 81:3018–3023
Meriggiola MC, Bremner WJ, Constantino A, Di Cintio G, Flamigni C (1998) Low dose of cyproterone acetate and testosterone enanthate for contraception. Hum Reprod 13:1225–1229
Nieschlag E (1986) Reasons for abandoning immunization against FSH as an approach to male fertility regulation. In: Zatuchni GI, Goldsmith A, Spieler JM, Sciarra JJ (eds) Male contraception: advances and future prospects. Harper and Row, Philadelphia, pp 395–400
Nieschlag E (2002) Sixth Summit Meeting Consensus: Recommendations for Regulatory Approval for Hormonal Male Contraception. Int J Androl 25:375
Nieschlag E, Kamische A, Behre HM (2004) Hormonal male contraception: the essential role of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone-action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 685–714
Pangkahila W (1991) Reversible azoospermia induced by an androgen-progestagen combination regimen in Indonesian men. Int J Androl 44:248–256
Patanelli DJ (ed) (1977) Hormonal control of fertility. US Department of Health Education and Welfare, Washington
Pavlou SN, Brewer K, Farley MG, Lindner J, Bastias MC, Rogers BJ, Swift LL, Rivier JE, Vale WW, Conn PM, Herbert CM (1991) Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab 73:1360–1369
Schearer SB, Alvarez-Sanchez F, Anselmo J, Brenner P, Coutinho E, Latham-Faundes A, Frick J, Heinild B, Johansson EDB (1978) Hormonal contraception for men. Int J Androl (Suppl 2):680–712
Shaneyfelt T, Husein R, Bubley G, Mantzoros CS (2000) Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18:847–853
Singh J, O’Neill C, Handelsman DJ (1995) Induction of spermatogenesis by androgens in gonadotropin-deficient (hpg) mice. Endocrinology 136:5311–5321
Tapanainen JS, Aittomaki K, Min J, Vasivou T, Huhtaniemi IT (1997) Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor present variable suppression of spermatogenesis and fertility. Nat Genet 15:205–206
Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol R, Rivier J, Vale WW, Swerdloff RS (1992) Induction of azoospermia in normal men with combined Nal-Glu GnRH antagonist and testosterone enanthate. J Clin Endocrinol Metab 75:476–483
Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ (2003) Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88:4659–4667
Waites GMH (2003) Development of methods of male contraception: impact of the World Health Organization Task Force. Fertil Steril 80:1–15
WHO Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955–999
WHO Task Force on Methods for the Regulation of Male Fertility (1993) Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril 60:1062–1068
WHO Task Force on Methods for the Regulation of Male Fertility (1996) Contraceptive efficacy of testosterone-inducedazoospermia and oligozoospermia in normal men. Fertil Steril 65:821–829
Wu FCW, von Eckardstein A (2003) Androgens and coronary artery disease. Endocr Rev 24:183–217
Wu FCW, Farley TMM, Peregoudov A, Waites GMH, WHO Task Force on Methods for the Regulation of Male Fertility (1996) Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Fertil Steril 65:626–636
Bibliografia
Cohen-Kettenis PT (2001) Gender identity disorder in DSM? J Am Acad Child Adolesc Psychiatry 40:391
Cohen-Kettenis PT, van Goozen SH (1998) Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. Eur Child Adolesc Psychiatry 7:246–248
de Bruin MD, Coerts MJ, Greven AJ (2000) Speech therapy in the management of male-to-female transsexuals. Folia Phoniatr Logop 52:220–227
Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC et al (2003) Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf ) 58:562–571
Futterweit W (1998) Endocrine therapy of transsexualism and potential complications of long-term treatment. Arch Sex Behav 27:209–226
Giltay EJ, Gooren LJ (2000) Effects of sex steroid deprivation/ administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 85:2913–2921
Gooren L, Delemarre-van de Waal H (1996) Memo on the feasibility of endocrine interventions in juvenile transsexuals. J Psychol Hum Sex 8:69–74
Levy A, Crown A, Reid R (2003) Endocrine intervention for transsexuals. Clin Endocrinol (Oxf ) 59:409–418
Moore E, Wisniewski A, Dobs A (2003) Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 88: 3467–3473
Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ et al (2003) Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 88:5723–5729
Van Haarst EP, Newling DW, Gooren LJ, Asscheman H, Prenger DM (1998) Metastatic prostatic carcinoma in a male-to-female transsexual. Br J Urol 81:776
van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ (1997) Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf ) 47:337–342
van Kesteren P, Lips P, Gooren LJ, Asscheman H, Megens J (1998) Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf ) 48:347–354
Bibliografia
Alexander GM, Swerdloff RS, Wang C et al (1997) Androgenbehavior correlations in hypogonadal men and eugonadal men. I. Mood and response to auditory sexual stimuli. Horm Behav 31:110–119
Altwein JE, Keuler FU (2001) Oral treatment of erectile dysfunction with apomorphine SL. Urol Int 67:257–263
Anderson RA, Bancroft J, Wu FC (1992) The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 75:1503–1507
Bancroft J (1995) Are the effects of androgens on male sexuality noradrenergically mediated? Some consideration of the human. Neurosci Biobehav Rev 19:325–330
Bancroft J (2002) Biological factors in human sexuality. J Sex Res 39:15–21
Bancroft J, Wu FC (1983) Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 12: 59–66
Bennett AH, Carpenter AJ, Barada JH (1991) An improved vasoactive drug combination for a pharmacological erection program. J Urol 146:1564–1565
Buena F, Swerdloff RS, Steiner BS et al (1993) Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 59:1118–1123
Bukofzer S, Livesey N (2001) Safety and tolerability of apomorphine SL (Uprima). Int J Impot Res 13 (Suppl 3):S40–S44
Carani C, Granata AR, Fustini MF, Marrama P (1996) Prolactin and testosterone: their role in male sexual function. Int J Androl 19:48–54
Carson C, Giuliano F, Goldstein I et al (2004) The «effectiveness» scale-therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res 16:207–213
DeBusk R, Drory Y, Goldstein I et al (2000) Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol 86:175–181
De Rosa M, Zarrilli S, Vitale G et al (2004) Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 89:621–625
Finkelstein JW, Susman EJ, Chinchilli VM et al (1998) Effects of estrogen or testosterone on self-reported sexual responses and behaviors in hypogonadal adolescents. J Clin Endocrinol Metab 83:2281–2285
Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A (2004) Role of androgens in erectile function. J Urol 71 (6 Pt 1): 2358–2362
Gijs L, Gooren LJ (1996) Hormonal and psychopharmacological interventions in the treatment of paraphilias: an update. J Sex Res 33:273–290
Gooren LJ (1987) Androgen levels and sex functions in testosteronetreated hypogonadal men. Arch Sex Behav 16: 463–473
Gooren LJ, Bunck MC (2004) Androgen replacement therapy: present and future. Drugs 64:1861–1891
Gooren LJ, Kruijver FP (2002) Androgens and male behavior. Mol Cell Endocrinol 198:31–40
Grasswick LJ, Bradford JM (2003) Osteoporosis associated with the treatment of paraphilias: a clinical review of seven case reports. J Forensic Sci 48:849–855
Halbreich U, Kinon BJ, Gilmore JA, Kahn LS (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28 (Suppl 1):53–67
Halpern CT, Udry JR, Suchindran C (1998) Monthly measures of salivary testosterone predict sexual activity in adolescent males. Arch Sex Behav 27:445–465
Hatzichristou DG, Pescatori ES (2001) Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU Int 88 (Suppl 3):11–17
Heaton JP, Altwein JE (2001) The role of apomorphine SL in the treatment of male erectile dysfunction. BJU Int 88 (Suppl 3):36–38
Hellstrom WJ, Bennett AH, Gesundheit N et al (1996) A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology 48:851–856
Hutter AM Jr. (2004) Role of the cardiologist: clinical aspects of managing erectile dysfunction. Clin Cardiol 27 (4 Suppl 1): I3–I7
Jackson G (2003) Erectile dysfunction: a window of opportunity for preventing vascular disease? Int J Clin Pract 57:747
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 163:460–463
Kloner RA (2004) Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol 27 (4 Suppl 1):I20–I25
Martinez R, Puigvert A, Pomerol JM, Rodriguez-Villalba R (2003) Clinical experience with apomorphine hydrochloride: the first 107 patients. J Urol 170(6 Pt 1):2352–2355
Meston CM, Frohlich PF (2000) The neurobiology of sexual function. Arch Gen Psychiatry 57:1012–1030
Montague DK, Jarow J, Broderick GA et al (2004) AUA guideline on the pharmacologic management of premature ejaculation. J Urol 172:290–294
Montorsi F, Althof SE (2004) Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 63: 762–767
Morelli A, Filippi S, Mancina R et al (2004) Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145:2253–2263
Porst H (1996) The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 155: 802–815
Porst H (2004) [Erectile dysfunctionNew drugs with special consideration of the PDE 5 inhibitors]. Urologe A43: 820–828
Reffelmann T, Kloner RA (2003) Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108:239–244
Reilly DR, Delva NJ, Hudson RW (2000) Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. Can J Psychiatry 45:559–563
Rosen R, Altwein J, Boyle P et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44:637–649
Schiavi RC, Rehman J (1995) Sexuality and aging. Urol Clin North Am 22:711–726
Schlechte JA (2002) The macroprolactin problem. J Clin Endocrinol Metab 87:5408–5409
Seftel AD (2004) Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol 27 (4 Suppl 1):I14–I19
Seftel AD, Mohammed MA, Althof SE (2004) Erectile dysfunction: etiology, evaluation, and treatment options. Med Clin North Am 88:387–416
Udry JR, Billy JO, Morris NM, Groff TR, Raj MH (1985) Serum androgenic hormones motivate sexual behavior in adolescent boys. Fertil Steril 43:90–94
Waldinger MD (2004) Lifelong premature ejaculation: from authoritybased to evidence-based medicine. BJU Int 93: 201–207
Bibliografia
Abbou CC, Payan C et al (1995) Transrectal and transurethral hyperthermia versus sham treatment in benign prostatic hyperplasia: a doubleblind randomized multicentre clinical trial. The French BPH Hyperthermia. Br J Urol 76:619–624
Abrams PH, Griffiths DJ (1979) The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 51:129–134
Ahmed M, Bell T et al (1997) Transurethral microwave thermotherapy (Prostatron version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. Br J Urol 79:181–185
American Urological Association (2003) AUA guideline on the management of benign prostatic hyperplasia. American Urological Association, New York
Anderson PR, Hanlon AL et al (1998) Perineural invasion and Gleason 7–10 tumors predict increased failure in prostate cancer patients with pretreatment PSA < 10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 41:1087–1092
Bales GT, Chodak GW (1996) A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47(1A Suppl):38–43; discussion 48–53
Barry MJ, Fowler FJ Jr et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549–1557; discussion 1564
Blasko JC, Ragde H et al (1996) Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 23:633–650
Blasko JC, Grimm PD et al (2000) Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46: 839–850
Bolla M (1999) Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol 35 (Suppl 1): 23–25; discussion 26
Boyle P, Robertson C et al (2004) Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93: 751–756
Bruskewitz RC, Iversen P et al (1982) Value of postvoid residual urine determination in evaluation of prostatism. Urology 20:602–604
Bruskewitz R, Issa MM et al (1998) A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 159:1588–1593; discussion 1593–1594
Caine M (1986) The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 136:1–4
Caine M, Pfau A et al (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 48:255–263
Caine M, Perlberg S et al (1978) A placebo-controlled doubleblind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50:551–554
Carter HB, Walsh PC et al (2002) Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167:1231–1234
D’Ancona FC, Francisca EA et al (1997) High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of followup. J Urol 158: 120–125
Debruyne F, Barkin J et al (2004) Efficacy and safety of longterm treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46:488–495
Decensi A, Guarneri D et al (1991) Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP). Eur J Cancer 27:1100–1104
Denis LJ, Carnelro de Moura JL et al (1993) Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 42:119–129; discussion 129–130
Denis L, Griffiths K et al (1998) Proceedings of the 4th International Consultation on benign prostatic hyperplasia (BPH). 2–5 July 1997, Plymouth, UK
Desmond PM, Clark J et al (1993) Morbidity with contemporary prostate biopsy. J Urol 150(5 Pt 1):1425–1426
Drach GW, Layton TN et al (1979) Male peak urinary flow rate: relationships to volume voided and age. J Urol 122: 210–214
Eisenberger MA, O’Dwyer PJ et al (1986) Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol 4:414–424
Eisenberger MA, Blumenstein BA et al (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036–1042
Garnick MB (1986) Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology 27(1 Suppl):21–28
Girman CJ, Panser LA et al (1993) Natural history of prostatism: urinary flow rates in a community-based study. J Urol 150:887–892
Gleason DM, Bottaccini MR et al (1982) Urinary flow velocity as an index of male voiding function. J Urol 128:1363–1367
Gormley GJ, Stoner E et al (1992) The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327:1185–1191
Hahn P, Baral E et al (1996) Long-term outcome of radical radiation therapy for prostatic carcinoma: 1967–1987. Int J Radiat Oncol Biol Phys 34:41–47
Han M, Partin AW et al (2001) Long-term biochemical diseasefree and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555–565
Hendrikx AJ, Doesburg WH et al (1988) Effectiveness of ultrasound in the preoperative evaluation of patients with prostatism. Prostate 13:199–208
Hide IG, Gangi A (2004) Percutaneous vertebroplasty: history, technique and current perspectives. Clin Radiol 59: 461–467
Huggins C, Hodges CV (1941) Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic cancer of the prostate. Cancer Res 1:293–297
Huland H, Hubner D et al (1994) Systematic biopsies and digital rectal examination to identify the nerve-sparing side for radical prostatectomy without risk of positive margin in patients with clinical stage T2, N0 prostatic carcinoma. Urology 44:211–214
Iversen P (1998) Orchidectomy and oestrogen therapy revisited. Eur Urol 34 (Suppl 3):7–11
Iversen P, Tyrrell CJ et al (2000) Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 164:1579–1582
Jacobsen SJ, Jacobson DJ et al (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158:481–487
Khan K, Thompson W et al (1992) Transperineal percutaneous iridium-192 interstitial template implant of the prostate: results and complications in 321 patients. Int J Radiat Oncol Biol Phys 22:935–939
Kirby R (1998) Treatment options for early prostate cancer. Urology 52:948–962
Kuntz RM, Lehrich K (2002) Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.: a randomized prospective trial of 120 patients. J Urol 168(4 Pt 1):1465–1469
Kyprianou N, English HF et al (1990) Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748–3753
Laing AH, Ackery DM et al (1991) Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 64:816–822
Lechevallier E, Eghazarian C et al (1999) Effect of digital rectal examination on serum complexed and free prostate-specific antigen and percentage of free prostate-specific antigen. Urology 54:857–861
Marberger M, Harkaway R et al (2004) Optimising the medical management of benign prostatic hyperplasia. Eur Urol 45:411–419
Maulard-Durdux C, Dufour B et al (1996) Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 77:1144–1148
McConnell JD, Bruskewitz R et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557–563
McConnell JD, Roehrborn CG et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398
Mebust WK, Holtgrewe HL et al (1989) Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 141:243–247
Messing EM, Young TB et al (1992) Home screening for hematuria: results of a multiclinic study. J Urol 148(2 Pt 1):289–292
Mikolajczyk SD, Marks LS et al (2002) Free prostate-specific antigen in serum is becoming more complex. Urology 59:797–802
Oesterling JE, Jacobsen SJ et al (1993) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. J Am Med Assoc 270:860–864
Pavone-Macaluso M, de Voogt HJ et al (1986) Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a ran-domized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136:624–631
Peterson RE, Imperato-McGinley J et al (1977) Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Am J Med 62:170–191
Pilepich MV, Krall JM et al (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616–623
Prostate Cancer Trialist’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355:1491–1498
Roehrborn CG, Girman CJ et al (1997) Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 49:548–557
Roehrborn CG, Boyle P et al (1999) Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 54:662–669
Roehrborn CG, McConnell J et al (2000) Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR longterm efficacy and safety study. J Urol 163:13–20
Roehrborn CG, Malice M et al (2001) Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58:210–216
Roehrborn CG, Boyle P et al (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434–441
Saad F, Gleason DM et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468
Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566–1572
Schroder FH, Collette L et al (2000) Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer 82:283–290
Schulman CC, Cortvriend J et al (1999) Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, openlabel study. European Tamsulosin Study Group. Eur Urol 36:609–620
See WA, McLeod D et al (2001) The bicalutamide Early Prostate Cancer Program. Demography 6:43–47
See WA, Wirth MP et al (2002) Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 168: 429–435
Sgrignoli AR, Walsh PC et al (1994) Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol 152:1077–1081
Shapiro E, Hartanto V et al (1992) The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 21:297–307
Shearer RJ, Hendry WF et al (1973) Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45:668–677
Small EJ, Carroll PR (1994) Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408–410
Soloway MS, Matzkin H (1993) Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer 71 (Suppl 3):1083–1088
Soloway MS, Sharifi R et al (1995) Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154(2 Pt 1): 424–428
Sorensen PS, Borgensen SE et al (1990) Metastatic epidural spinal cord compression: results of treatment and survival. Cancer 65:1502–1510
Stamey TA, McNeal JE et al (1999) Biological determinants of cancer progression in men with prostate cancer. J Am Med Assoc 281:1395–1400
Storlie JA, Buckner JC et al (1995) Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76:96–100
Tannock I F, Osoba D et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764
Tannock IF, de Wit R et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79:235–246
Thompson IM, Goodman PJ et al (2003a) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224
Thompson IM, Klein EA et al (2003b) Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 44:650–655
Walsh PC, Partin AW et al (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152(5 Pt 2):1831–1836
Wasson JH, Reda DJ et al (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 332:75–79
Weill A, Chiras J et al (1996) Spinal metastases: indications for and results of percutaneous injection of acrylic surgical cement. Radiology 199:241–247
Zietman AL, Coen JJ et al (1995) The treatment of prostate cancer by conventional radiation therapy: an analysis of long term outcome. Int J Radiat Oncol Biol Phys 32:287–292
Bibliografia
Delhez M, Hansenne M, Legros JJ (2003) Andropause and psychopathology: minor symptoms rather than pathological ones. Psychoneuroendocrinology 28:863–874
Gooren L (2003) Androgen deficiency in the aging male: benefits and risks of androgen supplementation. J Steroid Biochem Mol Biol 85:349–355
Gruenewald DA, Matsumoto AM (2003) Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 51:101–115
Hayes FJ (2000) Testosterone-fountain of youth or drug of abuse. J Clin Endocrinol Metab 85:3020–3023
Holmang S, Marin P, Lindstedt G, Hedelin H (1993) Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middleaged men. Prostate 23:99–106
Kelleher S, Conway AJ, Handelsman DJ (2004) Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 89:3813–3817
Morley JE, Perry HM (2003) Androgen treatment of male hypogonadism in older males. J Steroid Biochem Mol Biol 85:367–373
Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM 3rd (2000) Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49:1239–1242
Swerdloff RS, Wang C (2004) Androgens and the ageing male. Best Pract Res Clin Endocrinol Metab 18:349–362
Tenover JL (1999) Testosterone replacement therapy in older adult men. Int J Androl 22:300–306
Vanderschueren D, Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R (2000) An aged rat model of partial androgen deficiency: prevention of both loss of bone and lean body mass by low-dose androgen replacement. Endocrinology 141:1642–1647
Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C (2004) Androgens and bone. Endocr Rev 25:389–425
Vermeulen A (2001) Androgen replacement therapy in the aging male-a critical evaluation. J Clin Endocrinol Metab 86:2380–2390
Wu FC, von Eckardstein A (2003) Androgens and coronary artery disease. Endocr Rev 24:183–217
Bibliografia
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
Assmann T, Arens A, Becker-Wegerich P, Schuppe HC, Lehmann P (1999) Acne fulminans, sternoclavicular bone lesions and azoospermia following abuse of anabolic steroids [in German]. Z Hautkr 74:570–572
Bagatell CJ, Bremner WJ (1996) Androgens in men-uses and abuses. N Engl J Med 334:707–714
Bahrke M, Yesalis CE, Kopstein AN, Stephens JA (2000) Risk factors for anabolic-androgenic steroid use among adolescents. Sports Med 29:1–9
Basaria S, Wahlstrom JT, Dobs AS (2001) Clinical review 138: anabolicandrogenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 86:5108–5117
Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnel TJ, Tricker R, Shirazi A, Casaburi R (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335:1–7
Bhasin S, Woodhouse L, Storer TW (2001) Proof of the effect of testosterone on skeletal muscle. J Endocrinol 170:27–38
Bhasin S, Storer TW, Singh AB, Woodhouse L, Singh R, Artaza J, Taylor WE, Sinha-Hikim I, Jasuja R, Gonzalez-Cadavid N (2004) Testosterone effects on the skeletal muscle. In: Nieschlag E, Behre HM (eds) Testosterone—action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 715–735
Blouin AG, Goldfield GS (1995) Body image and steroid use in male bodybuilders. Int J Eat Disord 18:159–165
Boos C, Wulff P, Kujath P, Bruch H-P (1998) Drug abuse among recreational athletes in leisure sports [in German]. Dt ärztebl 95:A953–A957
Brower KJ (2002) Anabolic steroid abuse and dependence. Curr Psychiatry Rep 4:377–387
Buckley WE, Yesalis CE, Friedl KE, Anderson WA, Streit AL, Wright JE (1988) Estimated prevalence of anabolic steroid use among male high school seniors. J Am Med Assoc 260:3441–3445
Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang YC, Hatton CK (2004) Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Spectrom 18: 1245–1249
Choi PY, Pope HG Jr, Olivardia R (2002) Muscle dysmorphia: a new syndrome in weightlifters. Br J Sports Med 36:375–376
Dawson RT (2001) Drugs in sport-the role of the physician. J Endocrinol 170:55–61
Death AK, McGrath KC, Kazlauskas R, Handelsman DJ (2004) Tetrahydrogestrinone is a potent androgen and progestin. J Clin Endocrinol Metab 89:2498–2500
Drenowski A, Yee DK (1987) Men and body image: are males satisfied with their body weight? Psychosom Med 49:626–634
Duchaine D (1989) Underground steroid handbook II. HLR Technical Books, Venice
Durant RH, Rickert VI, Ashworth CS, Newman C, Slavens G (1993) Use of multiple drugs among adolescents who use anabolic steroids. N Engl J Med 328:922–926
Eklof AC, Thurelius AM, Garle M, Rane A, Sjoqvist F (2003) The antidoping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol 59: 571–577
Elashoff JD, Jacknow AD, Shain SG, Braunstein GD (1991) Effects of anabolic-androgenic steroids on muscular strength. Ann Intern Med 115:387–393
Franke WW, Berendonk B (1997) Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 43:1262–1279
Gazvani MR, Buckett W, Luckas MJM, Aird IA, Hipkin LJ, Lewis-Jones DI (1997) Conservative management of azoospermia following steroid abuse. Hum Reprod 12:1706–1708
Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Schänzer W (2004) Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids-results of an international study. Int J Sports Med 25:124–129
Handelsman DJ (2004) Designer androgens in sport: when too much is never enough. Sci STKE 244:41
Handelsman DJ, Gupta (1997) Prevalence and risk factors for anabolicandrogenic steroid abuse in Australian high school students. Int J Androl 20:159–164
Hartgens F, Rietjens G; Keizer HA, Kuipers H, Wolffenbuttel BH (2004) Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 38:253–259
International Olympic Committee (1999) Lausanne declaration on doping in sport. IOC, Lausanne
Jockenhövel F (2002) Männlicher Hypogonadismus-aktuelle Aspekte der Androgensubstitution, 2nd edn. Uni-Med, Bremen
Johnsen MD (1990) Anabolic steroid use in adolescent athletes. Pediatr Clin North Am 37:1111–1123
Jung A, Schill WB, Schuppe HC (2003) Persistent hypogonadotrophic hypogonadism after abuse of anabolic steroids [in German]. JDDG 1 (Suppl 1):S43
Karila T, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppälä T (2003) Dose-dependent increase in left ventricular mass in power athletes and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 24:337–343
Karila T, Hovatta O, Seppälä T (2004) Concomitant abuse of anabolic androgenic steroids and human chorionic gonadotrophin impairs spermatogenesis in power athletes. Int J Sports Med 25:257–263
Knuth UA, Maniera H, Nieschlag E (1989) Anabolic steroids and semen parameters in bodybuilders. Fertil Steril 52:1041–1047
Kochakian CD (1976) Anabolic-androgenic steroids. In: Handbook of experimental pharmacology, Vol 43. Springer, Berlin Heidelberg New York
Liu PY, Handelsman DJ (2004) Androgen therapy in non-gonadal disease. In: Nieschlag E, Behre HM (eds) Testosterone-action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 445–495
Mangweth B, Pope HG, Kemmler G, Ebenbichler C, Hausmann A, De Col C, Kreutner B, Kinzl J, Biebl W (2001) Body image and psychopathology in male bodybuilders. Psychother Psychosom 70:38–43
Menon DK (2003) Successful treatment of anabolic steroidinduced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril 79 (Suppl 3):1659–1661
Mottram DR, George AJ (2000) Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab 14:55–69
Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FCW (2004) Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10:409–419
Noakes TD (2004) Tainted glory—doping and athletic performance. N Engl J Med 351:847–849
Pope HG, Katz DL (1994) Psychiatric and medical effects of anabolicandrogenic steroid abuse. Arch Gen Psychiatry 51: 375–382
Pope HG, Phillips KA, Olivardia R (2000) The Adonis complex: the secret crisis of male body obsession. Free Press, New York
Saugy M, Cardis C, Robinson N, Schweizer C (2000) Test methods: anabolics. Baillieres Best Pract Res Clin Endocrinol Metab 14:111–133
Schänzer W (1998) Abuse of androgens and detection of illegal use. In: Nieschlag E, Behre HM (eds) Testosterone—action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 545–565
Schänzer W (2004) Abuse of androgens and detection of illegal use. In: Nieschlag E, Behre HM (eds) Testosterone—action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 715–735
Schürmeyer TH, Knuth UA, Belkien L, Nieschlag E (1984) Reversible azoospermia induced by anabolic steroid 19-nortestosterone. Lancet 1:417–420
Soe KL, Soe M, Gluud C (1992) Liver pathology associated with the use of anabolic-androgenic steroids. Liver 12:73–79
Tan RS, Vasudevan D (2003) Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril 79:203–205
Torres-Calleja J, Gonzales-Unzaga M, DeCelis-Carrillo R, Calzada-Sanchez L, Pedron N (2001) Effect of androgenic anabolic steroids on sperm quality and serum hormone levels in adult male bodybuilders. Life Sci 68:1769–1774
Turek PJ, Williams RH, Gilbaugh JH, Lipshultz LI (1995) The reversibility of anabolic steroid-induced azoospermia. J Urol 153:1628–1630
Van Breda E, Keizer HA, Kuipers H, Wolffenbuttel BH (2003) Androgenic anabolic steroid use and severe hypothalamicpituitary dysfunction: a case study. Int J Sports Med 24:195–196
Verroken M (2000) Drug use and abuse in sport. Baillieres Best Pract Res Clin Endocrinol Metab 14:1–23
Wade N (1972) Anabolic steroids: doctors denounce them but athletes aren’t listening. Science 176:1399–1403
Wilson JD (1988) Androgen abuse by athletes. Endocr Rev 9:181–199
Bibliografia
Arlt W, Haas J, Callies F, Reincke M, Hubler D, Oettel M, Ernst M, Schulte HM, Allolio B (1999) Biotransformation of oral dehydroepi and rosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab 84:2170–2176
Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr. (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13:395–400
Bubenik GA (2002) Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 47:2336–2348
Calabrese V, Scapagnini G, Giuffrida SA, Bates TE, Clark JB (2001) Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem Res 26:739–764
Callahan D (2000) Death and the research imperative. N Engl J Med 342:654–656
Comhaire F, Mahmoud A (2004) Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. Aging Male 7:155–169
Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR (2001) Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormonereleasing hormone-induced growth hormone and insulinlike growth factor-1 secretion in early and late postmenopausal women. Fertil Steril 76:241–248
Hautanen A, Manttari M, Manninen V, Tenkanen L, Huttunen JK, Frick MH, Adlercreutz H (1994) Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 105:191–200
Higuchi Y, Saeki N, Iuchi T, Uchino Y, Tatsuno I, Uchida D, Tanaka T, Noguchi Y, Nakamura S, Yasuda T, Yamaura A, Sunami K, Oka Y, Uozumi A (2000) Incidence of malignant tumors in patients with acromegaly. Endocr J 47 [Suppl]:S57–S60
Hinson JP, Brooke A, Raven PW (2003) Therapeutic uses of dehydroepiandrosterone. Curr Opin Investig Drugs 4:1205–1208
Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK (2000) Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J Clin Endocrinol Metab 85:4650–4656
Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA (1997) Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82:727–734
Khaw KT (1996) Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. J Endocrinol 150 [Suppl]:S149–S153
Klapper W, Parwaresch R, Krupp G (2001) Telomere biology in human aging and aging syndromes. Mech Ageing Dev 122:695–712
Koh E, Kanaya J, Namiki M (2001) Adrenal steroids in human prostatic cancer cell lines. Arch Androl 46:117–125
Labrie F, Belanger A, Cusan L, Candas B (1997) Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 82:2403–2409
Labrie F, Luu-The V, Labrie C, Simard J (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 22: 185–212
Legrain S, Massien C, Lahlou N, Roger M, Debuire B, Diquet B, Chatellier G, Azizi M, Faucounau V, Porchet H, Forette F, Baulieu EE (2000) Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab 85:3208–3217
Lissoni P (1998) Melatonin and cancer treatment. In: Watson RR (eds) Melatonin in the promotion of health. CRC, London, pp 175–190
Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G, Frigerio F (1994) A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 80:464–467
Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, Schambelan M (2001) The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86:3480–3487
Lusardi P, Piazza E, Fogari R (2000) Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol 49:423–427
Messner M, Huether G, Lorf T, Ramadori G, Schworer H (2001) Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 69:543–551
Montanini V, Simoni M, Chiossi G, Baraghini GF, Velardo A, Baraldi E, Marrama P (1988) Age-related changes in plasma dehydroepiandrosterone sulphate, cortisol, testosterone and free testosterone circadian rhythms in adult men. Horm Res 29:1–6
Newcomer JW, Craft S, Hershey T, Askins K, Bardgett ME (1994) Glucocorticoid-induced impairment in declarative memory performance in adult humans. J Neurosci 14:2047–2053
Nippoldt TB, Nair KS (1998) Is there a case for DHEA replacement? Baillieres Clin Endocrinol Metab 12:507–520
Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730–2734
Porsova-Dutoit I, Sulcova J, Starka L (2000) Do DHEA/DHEAS play a protective role in coronary heart disease? Physiol Res 49 [Suppl 1]:S-3–S56
Sack RL, Brandes RW, Kendall AR, Lewy AJ (2000) Entrainment of freerunning circadian rhythms by melatonin in blind people. N Engl J Med 343:1070–1077
Schiller CD, Schneider MR, Hartmann H, Graf AH, Klocker H, Bartsch G (1991) Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma. Urol Res 19:7–13
Tchernof A, Labrie F (2004) Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 151:1–14
Thijs L, Fagard R, Forette F, Nawrot T, Staessen JA (2003) Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta Cardiol 58:403–410
Villareal DT, Holloszy JO, Kohrt WM (2000) Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf) 53:561–568
Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA
Cunningham J (1995) The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 80:153–159
Weill-Engerer S, David JP, Sazdovitch V, Liere P, Schumacher M, Delacourte A, Baulieu EE, Akwa Y (2003) In vitro metabolism of dehydroepiandrosterone (DHEA) to 7 alpha-hydroxy-DHEA and Delta5-androstene-3beta,17beta-diol in specific regions of the aging brain from Alzheimer’s and non-demented patients. Brain Res 969:117–125
Wolf OT, Neumann O, Hellhammer DH, Geiben AC, Strasburger CJ, Dressendorfer RA, Pirke KM, Kirschbaum C (1997) Effects of a twoweek physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 82:2363–2367
Bibliografia
Adam O (2003) Dietary fatty acids and immune reactions in synovial tissue. Eur J Med Res 8:381–387
Adlercreutz H (1988) Lignans and phytoestrogens. Possible preventive role in cancer. Front Gastrointest Res 14:165–176
Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Mori M (2002) Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 32: 296–300
Balon TW, Jasman AP, Zhu JS (2002) A fermentation product of Cordyceps sinensis increases whole-body insulin sensitivity in rats. J Altern Complement Med 8:315–323
Bayne CW, Ross M, Donnelly F, Habib FK (2000) The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 164: 876–881
Behrens WA, Madere R (1987) Mechanisms of absorption, transport and tissue uptake of RRR-alpha-tocopherol and d-gamma-tocopherol in the white rat. J Nutr 117:1562–1569
Bernard D, Christophe A, Delanghe J, Langlois M, de Buyzere M, Comhaire F (2003) The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. Redox Rep 8:41–46
Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB (2004) Effect of Vitamin D on falls: a meta-analysis. J Am Med Assoc 291:1999–2006
Blair I (2004) First evidence COX-2 enzymes can regulate DNA damage. ASBMB Annual Meeting and 8th IUBMB Conference, 12–16 June 2004, Boston, Mass., http://www.bio.com
Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R (2002) Safety considerations for statins. Curr Opin Lipidol 13: 637–644
Boyle P, Robertson C, Lowe F, Roehrborn C (2000) Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 55:533–539
Brooks JD, Ward WE, Lewis JE, Hilditch J, Nickell L, Wong E, Thompson LU (2004) Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. Am J Clin Nutr 79:318–325
Clarke R, Armitage J (2000) Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost 26:341–348
Combs GF (2004) Status of selenium in prostate cancer prevention. Br J Cancer 91:195–199
Comhaire F, Mahmoud A (2004) Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. Ageing Male 7:155–169
Comhaire FH, Christophe AB, Zalata AA, Dhooge WS, Mahmoud AM, Depuydt CE (2000) The effects of combined conventional treatment, oral antioxidants and essential fatty acids on sperm biology in subfertile men. Prostaglandins Leukot Essent Fatty Acids 63:159–165
Cooney RV, Franke AA, Harwood PJ, Hatch-Pigott V, Custer LJ, Mordan LJ (1993) Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alpha-tocopherol. Proc Natl Acad Sci USA 90:1771–1775
Cristoni A, Di Pierro F, Bombardelli E (2000) Botanical derivatives for the prostate. Fitoterapia 71 [Suppl 1]:S21–S28
Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA (2004) Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 93:1139–1150
Daynes RA, Enioutina EY, Jones DC (2003) Role of redox imbalance in the molecular mechanisms responsible for immunosenescence. Antioxid Redox Signal 5:537–548
De Smet PA (2002) Herbal remedies. N Engl J Med 347:2046–2056
Denis L, Morton MS, Griffiths K (1999) Diet and its preventive role in prostatic disease. Eur Urol 35:377–387
Dias C, Borralho Graca JA, Lurdes GM (2000) Scilla maderensis, TLC screening and positive inotropic effect of bulb extracts. J Ethnopharmacol 71:487–492
Dinckal MH, Aksoy N, Aksoy M, Davutoglu V, Soydinc S, Kirilmaz A, Dinckal N, Akdemir I (2003) Effect of homocysteinelowering therapy on vascular endothelial function and exercise performance in coronary patients with hyperhomocysteinaemia. Acta Cardiol 58:389–396
Farmer JA (2003) Statins and myotoxicity. Curr Atheroscler Rep 5:96–100
Fawzi WW, Msamanga GI, Spiegelman D, Wei R, Kapiga S, Villamor E, Mwakagile D, Mugusi F, Hertzmark E, Essex M, Hunter DJ (2004) A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 351:23–32
Freeman VL, Meydani M, Yong S, Pyle J, Wan Y, Arvizu-Durazo R, Liao Y (2000) Prostatic levels of tocopherols, carotenoids, and retinol in relation to plasma levels and self-reported usual dietary intake. Am J Epidemiol 151:109–118
Giovannucci E (2000) Gamma-tocopherol: a new player in prostate cancer prevention? J Natl Cancer Inst 92:1966–1967
Hadjiev D, Yancheva S (1976) Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung 26:1947–1950
Haggans CJ, Hutchins AM, Olson BA, Thomas W, Martini MC, Slavin JL (1999) Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer 33:188–195
Haggans CJ, Travelli EJ, Thomas W, Martini MC, Slavin JL (2000) The effect of flaxseed and wheat bran consumption on urinary estrogen metabolites in premenopausal women. Cancer Epidemiol Biomarkers Prev 9:719–725
Handelman GJ, Epstein WL, Peerson J, Spiegelman D, Machlin LJ, Dratz EA (1994) Human adipose alpha-tocopherol and gamma-tocopherol kinetics during and after 1 y of alpha-tocopherol supplementation. Am J Clin Nutr 59:1025–1032
Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, Morris JS, Comstock GW (2000) Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92:2018–2023
Hsu CC, Huang YL, Tsai SJ, Sheu CC, Huang BM (2003) In vivo and in vitro stimulatory effects of Cordyceps sinensis on testosterone production in mouse Leydig cells. Life Sci 73:2127–2136
Huang BM, Hsu CC, Tsai SJ, Sheu CC, Leu SF (2001a) Effects of Cordyceps sinensis on testosterone production in normal mouse Leydig cells. Life Sci 69:2593–2602
Huang BM, Ju SY, Wu CS, Chuang WJ, Sheu CC, Leu SF (2001b) Cordyceps sinensis and its fractions stimulate MA-10 mouse Leydig tumor cell steroidogenesis. J Androl 22:831–837
Huang BM, Hsiao KY, Chuang PC, Wu MH, Pan HA, Tsai SJ (2004) Upregulation of steroidogenic enzymes and ovarian 17beta-estradiol in human granulosa-lutein cells by Cordyceps sinensis mycelium. Biol Reprod 70:1358–1364
Ichihara K, Satoh K, Yamamoto A, Hoshi K (1999) [Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?]. [Japanese] Nippon Yakurigaku Zasshi Folia Pharmacol Jpn 114 [Suppl 1]:142P–149P
Jakobisiak M, Lasek W, Golab J (2003) Natural mechanisms protecting against cancer. Immunol Lett 90:103–122
Karpati E, Szporny L (1976) General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneimittelforschung 26:1908–1912
Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG (2002) MTHFR 677C-> T polymorphism and risk of coronary heart disease: a meta-analysis. J Am Med Assoc 288: 2023–2031
Koh JH, Kim KM, Kim JM, Song JC, Suh HJ (2003) Antifatigue and antistress effect of the hot-water fraction from mycelia of Cordyceps sinensis. Biol Pharm Bull 26:691–694
Kondas J, Philipp V, Dioszeghy G (1996) Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol Nephrol 28:767–772
Kornitzer M, Bara L (1989) Clinical and anthropometric data, blood chemistry and nutritional patterns in the Belgian population according to age and sex. For the B.I.R.N.H. Study Group. Acta Cardiol 44:101–144
Kornitzer M, Valente F, De Bacquer D, Neve J, De Backer G (2004) Serum selenium and cancer mortality: a nested casecontrol study within an age-and sex-stratified sample of the Belgian adult population. Eur J Clin Nutr 58:98–104
Kringstein P, Cederbaum AI (1995) Boldine prevents human liver microsomal lipid peroxidation and inactivation of cytochrome P4502E1. Free Radic Biol Med 18:559–563
Lankin VZ, Tikhaze AK, Kukharchuk VV, Konovalova GG, Pisarenko OI, Kaminnyi AI, Shumaev KB, Belenkov YN (2003) Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Mol Cell Biochem 249:129–140
Lesourd B (2004) Nutrition: a major factor influencing immunity in the elderly. J Nutr Health Aging 8:28–37
Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, Ma J (2004) A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 96:696–703
Martinez GR, Loureiro AP, Marques SA, Miyamoto S, Yamaguchi LF, Onuki J, Almeida EA, Garcia CC, Barbosa LF, Medeiros MH, Di Mascio P (2003) Oxidative and alkylating damage in DNA. Mutat Res 544:115–127
Matkovics B, Szabo L, Kiss B, Szpornyi L (1991) Effect of ethyl apovincaminate on the utilization of 14C-glucoses by rat brain in vitro. Arzneimittelforschung 41:107–108
McAlindon TE, LaValley MP, Gulin JP, Felson DT (2000) Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. J Am Med Assoc 283:1469–1475
McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042–2049
Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F (2000) Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16 alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11:635–640
Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230–236
Ohshima H, Tatemichi M, Sawa T (2003) Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 417:3–11
Oranje WA, Sels JP, Rondas-Colbers GJ, Lemmens PJ, Wolffenbuttel BH (2001) Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 311:91–94
Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP (2003) Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors 18:113–124
Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY (2003) Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 163:1514–1522
Romics I, Schmitz H, Frang D (1993) Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. Int Urol Nephrol 25:565–569
Rötter W (1958) [Indications for therapy with digitaloids (Scilla maritima)] Münch Med Wochenschr 100:812–815
Satoh K, Ichihara K (2000) Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol 35(2):256–262
Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC, Raab CE, Yu NX, Lankas GR, Frederick CB (2004) Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 194:10–23
Schmeda-Hirschmann G, Rodriguez JA, Theoduloz C, Astudillo SL, Feresin GE, Tapia A (2003) Free-radical scavengers and antioxidants from Peumus boldus Mol. (“Boldo”). Free Radic Res 37:447–452
Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM (2002) Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. J Am Med Assoc 288:973–979
Solti F, Iskum M, Czako E (1976) Effect of ethyl apovincaminate on the cerebral circulation. Studies in patients with obliterative cerebral arterial disease. Arzneimittelforschung 26: 1945–1947
Speisky H, Cassels BK (1994) Boldo and boldine: an emerging case of natural drug development. Pharmacol Res 29:1–12
Stepanov VN, Siniakova LA, Sarrazin B, Raynaud JP (1999) Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. Adv Ther 16:231–241
Tesseris J, Roggen G, Caracalos A, Triandafillou D (1975) Effects of vincamin on cerebral metabolism. Eur Neurol 13: 195–202
Thambyrajah J, Landray MJ, Jones HJ, McGlynn FJ, Wheeler DC, Townend JN (2001) A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol 37:1858–1863
Vacherot F, Azzouz M, Gil-Diez-De-Medina S, Colombel M, De La TA, Lefrere Belda MA, Abbou CC, Raynaud JP, Chopin DK (2000) Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon) in benign prostatic hyperplasia. Prostate 45:259–266
Vamosi B, Molnar L, Demeter J, Tury F (1976) Comparative study of the effect of ethyl apovincaminate and xantinol nicotinate in cerebrovascular diseases. Immediate drug effects on the concentrations of carbohydrate metabolites and electrolytes in blood and CSF. Arzneimittelforschung 26:1980–1984
van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der KM, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350:2033–2041
Vermeulen EG, Stehouwer CD, Twisk JW, van den BM, de Jong SC, Mackaay AJ, van Campen CM, Visser FC, Jakobs CA, Bulterjis EJ, Rauwerda JA (2000) Effect of homocysteinelowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 355:517–522
Weisser H, Tunn S, Behnke B, Krieg M (1996) Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5 alphareductase activity in human benign prostatic hyperplasia. Prostate 28:300–306
Weisser H, Behnke B, Helpap B, Bach D, Krieg M (1997) Enzyme activities in tissue of human benign prostatic hyperplasia after three months’ treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur Urol 31:97–101
Westerlind KC (2003) Physical activity and cancer prevention-mechanisms. Med Sci Sports Exerc 35:1834–1840
Wilt TJ, Ishani A, Rutks I, MacDonald R (2000) Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3:459–472
Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61:82–88
Zhao CS, Yin WT, Wang JY, Zhang Y, Yu H, Cooper R, Smidt C, Zhu JS (2002) CordyMax Cs-4 improves glucose metabolism and increases insulin sensitivity in normal rats. J Altern Complement Med 8:309–314
Bibliografia
Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, Hase T, Arosemena PJ, Kellis JT Jr., Vickery LE (1993) Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 44: 147–153
Aydin S, Inci O, Alagol B (1995) The role of arginine, indomethacin and kallikrein in the treatment of oligoasthenospermia. Int Urol Nephrol 27:199–202
Bartellini M, Canale D, Izzo PL, Giorgi PM, Meschini P, Menchini-Fabris GF (1987) L-Carnitine and acetylcarnitine in human sperm with normal and reduced motility. Acta Eur Fertil 18:29–31
Baumann J, von Bruchhausen F, Wurm G (1980) Flavonoids and related compounds as inhibition of arachidonic acid peroxidation. Prostaglandins 20:627–639
Bernard D, Christophe A, Delanghe J, Langlois M, de Buyzere M, Comhaire F (2003) The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. Redox Rep 8:41–46
Bonde JP, Joffe M, Apostoli P, Dale A, Kiss P, Spano M, Caruso F, Giwercman A, Bisanti L, Porru S, Vanhoorne M, Comhaire F, Zschiesche W (2002) Sperm count and chromatin structure in men exposed to inorganic lead: lowest adverse effect levels. Occup Environ Med 59:234–242
Cho KJ, Yun CH, Packer L, Chung AS (2001) Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus ma ritima on the expression of proinflammatory cytokines. Ann NY Acad Sci 928:141–156
Christophe A, Zalata A, Mahmoud A, Comhaire F (1998) Fatty acid composition of sperm phospholipids and its nutritional implications. Middle East Fertil Soc J 3:46–53
Cinti DL, Cook L, Nagi MN, Suneja SK (1992) The fatty acid chain elongation system of mammalian endoplasmic reticulum. Prog Lipid Res 31:1–51
Comhaire F (2000) Clinical andrology: from evidence-base to ethics. The “E” quintet in clinical andrology. Hum Reprod 15:2067–2071
Comhaire FH, Mahmoud AM (2004) Editorial commentary. J Androl 25:771–772
Comhaire F, Vermeulen L (1983) Effect of high dose oral kallikrein treatment in men with idiopathic subfertility: evaluation by means of in vitro penetration test of zona free hamster ova. Int J Androl 6:168–172
Comhaire FH, Christophe AB, Zalata AA, Dhooge WS, Mahmoud AM, Depuydt CE (2000) The effects of combined conventional treatment, oral antioxidants and essential fatty acids on sperm biology in subfertile men. Prostaglandins Leukot Essent Fatty Acids 63:159–165
Comhaire FH, Garem YFE, Mahmoud A, Eertmans F, Schoonjans F (2005) Combined conventional/antioxidant “Astaxanthin” treatment for male infertility: a double blind randomized trial. Asian J Androl 7:257–262
Costa M, Canale D, Filicori M, D’lddio S, Lenzi A (1994) L-Carnitine in idiopathic asthenozoospermia: a multicenter study. Italian Study Group on Carnitine and Male Infertility. Andrologia 26:155–159
Dawson EB, Harris WA, Teter MC, Powell LC (1992) Effect of ascorbic acid supplementation on the sperm quality of smokers. Fertil Steril 58:1034–1039
De Aloysio D, Mantuano R, Mauloni M, Nicoletti G (1982) The clinical use of arginine aspartate in male infertility. Acta Eur Fertil 13:133–167
DeBaun MR, Niemitz EL, Feinberg AP (2003) Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet 72:156–160
Depuydt CE, Mahmoud AM, Dhooge WS, Schoonjans FA, Comhaire FH (1999) Hormonal regulation of inhibin B secretion by immature rat Sertoli cells in vitro: possible use as a bioassay for estrogen detection. J Androl 20:54–62
Edwards RG, Ludwig M (2003) Are major defects in children conceived in vitro due to innate problems in patients or to induced genetic damage? Reprod Biomed Online 7:131–138
Fraga CG, Motchnik PA, Shigenaga MK, Helbock HJ, Jacob RA, Ames BN (1991) Ascorbic acid protects against endogenous oxidative DNA damage in human sperm. Proc Natl Acad Sci USA 88:11003–11006
Glezerman M, Lunenfeld E, Potashnik G, Huleihel M, Soffer Y, Segal S (1993) Efficacy of kallikrein in the treatment of oligozoospermia and asthenozoospermia: a double-blind trial. Fertil Steril 60:1052–1056
Golan R, Weissenberg R, Lewin LM (1984) Carnitine and acetylcarnitine in motile and immotile human spermatozoa. Int J Androl 7:484–494
Gonzales GF, Ruiz A, Gonzales C, Villegas L, Cordova A (2001a) Effect of Lepidium meyenii (Maca) roots on spermatogenesis of male rats. Asian J Androl 3:231–233
Gonzales GF, Cordova A, Gonzales C, Chung A, Vega K, Villena A (2001b) Lepidium meyenii (Maca) improved semen parameters in adult men. Asian J Androl 3:301–303
Goto S, Kogure K, Abe K, Kimata Y, Kitahama K, Yamashita E, Terada H (2001) Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim Biophys Acta 1512:251–258
Green NS (2004) Risks of birth defects and other adverse outcomes associated with assisted reproductive technology. Pediatrics 114:256–259
Hansen M, Kurinczuk JJ, Bower C, Webb S (2002) The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med 346:725–730
Hughes CM, Lewis SE, McKelvey-Martin VJ, Thompson W (1998) The effects of antioxidant supplementation during Percoll preparation on human sperm DNA integrity. Hum Reprod 13:1240–1247
Hurtado de Catalfo GE, de Gomez Dumm IN (2002) Polyunsaturated fatty acid biosynthesis from [1–14 C]20:3 n−6 acid in rat cultured Sertoli cells. Linoleic acid effect. Int J Biochem Cell Biol 34:525–532
Irvine DS, Twigg JP, Gordon EL, Fulton N, Milne PA, Aitken RJ (2000) DNA integrity in human spermatozoa: relationships with semen quality. J Androl 21:33–44
Iwamoto T, Hosoda K, Hirano R, Kurata H, Matsumoto A, Miki W, Kamiyama M, Itakura H, Yamamoto S, Kondo K (2000) Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscler Thromb 7:216–222
Jeulin C, Lewin LM (1996) Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. Hum Reprod Update 2:87–102
Katz P, Nachtigall R, Showstack J (2002) The economic impact of the assisted reproductive technologies. Nat Cell Biol 4 [Suppl]:s29–s32
Keck C, Behre HM, Jockenhövel F, Nieschlag E (1994) Ineffectiveness of kallikrein in treatment of idiopathic male infertility: a double-blind, randomized, placebo-controlled trial. Hum Reprod 9:325–329
Kent-First MG, Kol S, Muallem A, Ofir R, Manor D, Blazer S, First N, Itskovitz-Eldor J (1996) The incidence and possible relevance of Ylinked microdeletions in babies born after intracytoplasmic sperm injection and their infertile fathers. Mol Hum Reprod 2:943–950
Kessopoulou E, Powers HJ, Sharma KK, Pearson MJ, Russell JM, Cooke ID, Barratt CL (1995) A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertil Steril 64:825–831
Kohengkul S, Tanphaichitr V, Muangmun V, Tanphaichitr N (1977) Levels of L-carnitine and L-O-acetylcarnitine in normal and infertile human semen: a lower level of L-O-acetycarnitine in infertile semen. Fertil Steril 28:1333–1336
Koudstaal J, Bruinse HW, Helmerhorst FM, Vermeiden JP, Willemsen WN, Visser GH (2000) Obstetric outcome of twin pregnancies after in-vitro fertilization: a matched control study in four Dutch University hospitals. Hum Reprod 15:935–940
Lambert RD (2002) Safety issues in assisted reproduction technology: the children of assisted reproduction confront the responsible conduct of assisted reproductive technologies. Hum Reprod 17:3011–3015
Lenzi A, Culasso F, Gandini L, Lombardo F, Dondero F (1993) Placebocontrolled, double-blind, cross-over trial of glutathione therapy in male infertility. Hum Reprod 8:1657–1662
Lenzi A, Lombardo F, Sgro P, Salacone P, Caponecchia L, Dondero F, Gandini L (2003) Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. Fertil Steril 79:292–300
Lewin A, Lavon H (1997) The effect of coenzyme Q10 on sperm motility and function. Mol Aspects Med 18 [Suppl]:S213–S219
Ma K, Sharkey A, Kirsch S, Vogt P, Keil R, Hargreave TB, McBeath S, Chandley AC (1992) Towards the molecular localisation of the AZF locus: mapping of microdeletions in azoospermic men within 14 subintervals of interval 6 of the human Y chromosome. Hum Mol Genet 1:29–33
Maher ER, Afnan M, Barratt CL (2003) Epigenetic risks related to assisted reproductive technologies: epigenetics, imprinting, ART and icebergs? Hum Reprod 18:2508–2511
Mahmoud AM, Comhaire FH, Depuydt CE (1998) The clinical and biologic significance of serum inhibins in subfertile men. Reprod Toxicol 12:591–599
Mahmoud A, Kiss P, Kaufman JM, Comhaire F, Asclepios (2000) The influence of age and lead exposure on inhibin B serum levels in men. Int J Androl 23 [Suppl 1]:PO94
Mayerhofer A, Meineke V, Köhn FM, Frungieri M (2002) O-03 Cyclooxygenase (COX-2) in male infertility: a new link between prostaglandins and testicular fibrosis? Andrologia 34:272–273
Meachem SJ, Nieschlag E, Simoni M (2001) Inhibin B in male reproduction: pathophysiology and clinical relevance. Eur J Endocrinol 145:561–571
Menchini-Fabris GF, Canale D, Izzo PL, Olivieri L, Bartelloni M (1984) Free L-carnitine in human semen: its variability in different andrologic pathologies. Fertil Steril 42:263–267
Moll AC, Imhof SM, Cruysberg JR, Schouten-van Meeteren AY, Boers M, van Leeuwen FE (2003) Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet 361:309–310
Moncada ML, Vicari E, Cimino C, Calogero AE, Mongioi A, D’Agata R (1992) Effect of acetylcarnitine treatment in oligoasthenospermic patients. Acta Eur Fertil 23:221–224
Palermo G, Joris H, Devroey P, Van Steirteghem AC (1992) Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 340:17–18
Pinborg A, Loft A, Schmidt L, Greisen G, Rasmussen S, Andersen AN (2004) Neurological sequelae in twins born after assisted conception: controlled national cohort study. BMJ 329:311
Pryor JP, Blandy JP, Evans P, Chaput DSD, Usherwood M (1978) Controlled clinical trial of arginine for infertile men with oligozoospermia. Br J Urol 50:47–50
Rohdewald P (2002) A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 40:158–168
Rolf C, Cooper TG, Yeung CH, Nieschlag E (1999) Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Hum Reprod 14:1028–1033
Roseff SJ, Gulati R (1999) Improvement of sperm quality by Pycnogenol. Eur Bull Drug Res 7:33–36
Ruiz-Pesini E, Alvarez E, Enriquez JA, Lopez-Perez MJ (2001) Association between seminal plasma carnitine and sperm mitochondrial enzymatic activities. Int J Androl 24:335–340
Saether T, Tran TN, Rootwelt H, Christophersen BO, Haugen TB (2003) Expression and regulation of delta 5-desaturase, delta 6-desaturase, stearoyl-coenzyme A (CoA) desaturase 1, and stearoyl-CoA desaturase 2 in rat testis. Biol Reprod 69:117–124
Schieve LA, Rasmussen SA, Buck GM, Schendel DE, Reynolds MA, Wright VC (2004) Are children born after assisted reproductive technology at increased risk for adverse health outcomes? Obstet Gynecol 103:1154–1163
Schill WB (1979) Treatment of idiopathic oligozoospermia by kallikrein: results of a double-blind study. Arch Androl 2:163–170
Schill WB, Krizic A, Rjosk H (1979) Determination of various semen parameters and sex hormone levels in subfertile men during kallikrein therapy. Adv Exp Med Biol 120A:537–546
Scott R, MacPherson A, Yates RW, Hussain B, Dixon J (1998) The effect of oral selenium supplementation on human sperm motility. Br J Urol 82:76–80
Sharpe RM (2003) The “oestrogen hypothesis” — where do we stand now? Int J Androl 26:2–15
Skakkebaek NE (2004) Testicular dysgenesis syndrome: new epidemiological evidence. Int J Androl 27:189–191
Soufir JC, Ducot B, Marson J, Jouannet P, Feneux D, Soumah A, Spira A (1984) Levels of seminal free L(−) carnitine in fertile and infertile men. Int J Androl 7:188–197
Steptoe PC, Edwards RG (1978) Birth after the reimplantation of a human embryo. Lancet 2:366
Stromberg B, Dahlquist G, Ericson A, Finnstrom O, Koster M, Stjernqvist K (2002) Neurological sequelae in children born after in-vitro fertilisation: a population-based study. Lancet 359:461–465
Sutcliffe AG, Taylor B, Li J, Thornton S, Grudzinskas JG, Lieberman BA (1999) Children born after intracytoplasmic sperm injection: population control study. Br Med J 318:704–705
Tanphaichitr N (1977) In vitro stimulation of human sperm motility by acetylcarnitine. Int J Fertil 22:85–91
Tiepolo L, Zuffardi O (1976) Localization of factors controlling spermatogenesis in the nonfluorescent portion of the human Y chromosome long arm. Hum Genet 34:119–124
Tran TN, Retterstol K, Christophersen BO (2003) Metabolism of long-chain polyunsaturated fatty acids in testicular cells. In: De Vriese SR, Christophe AB (eds) Male fertility and lipid metabolism. AOCS, Illinois, pp 11–22
van der Ven K, Peschka B, Montag M, Lange R, Schwanitz G, van der Ven HH, van der Ven K (1998) Increased frequency of congenital chromosomal aberrations in female partners of couples undergoing intracytoplasmic sperm injection. Hum Reprod 13:48–54
van Dissel-Emiliani FM, Grootenhuis AJ, De Jong FH, de Rooij DG (1989) Inhibin reduces spermatogonial numbers in testes of adult mice and Chinese hamsters. Endocrinology 125:1899–1903
Vanhoorne M, Comhaire F, De Bacquer D (1994) Epidemiological study of the effects of carbon disulfide on male sexuality and reproduction. Arch Environ Health 49:273–278
Virgili F, Kim D, Packer L (1998) Procyanidins extracted from pine bark protect alpha-tocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS Lett 431:315–318
Vitali G, Parente R, Melotti C (1995) Carnitine supplementation in human idiopathic asthenospermia: clinical results. Drugs Exp Clin Res 21:157–159
Voliani S, Bertozzi MA, Rossi P, Menchini-Fabris GF (2001) The treatment of male infertility with L-carnitine/L-acetyl carnitine. XVII National Congress, Societa Italiana Andrologia SIA, Venezia 2001, 8:122
Wang C, Makela T, Hase T, Adlercreutz H, Kurzer MS (1994) Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 50:205–212
Wennerholm U, Bergh C, Hamberger L, Lundin K, Nilsson L, Wikland M, Kallen B (2000) Incidence of congenital malformations in children born after ICSI. Hum Reprod 15: 944–948
Wildman REC, Medeiros DM (2000) Advanced human nutrition. CRC, London, pp 370–371
Wong WY, Merkus HM, Thomas CM, Menkveld R, Zielhuis GA, Steegers-Theunissen RP (2002) Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertil Steril 77:491–498
Zalata AA, Christophe AB, Depuydt CE, Schoonjans F, Comhaire FH (1998) The fatty acid composition of phospholipids of spermatozoa from infertile patients. Mol Hum Reprod 4:111–118
Zheng BL, He K, Kim CH, Rogers L, Shao Y, Huang ZY, Lu Y, Yan SJ, Qien LC, Zheng QY (2000) Effect of a lipidic extract from Lepidium meyenii on sexual behavior in mice and rats. Urology 55:598–602
Bibliografia
Alsina JC, Balda JAR, Sarrio AR, Fernandez AR, Trigo IC, Parga JLG, Batres CG, Escudero JR (2003) Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. Br J Obstet Gynaecol 110:1072–1077
Cantineau AE, Heineman MJ, Cohlen BJ (2003) Single versus double intrauterine insemination (IUI) in stimulated cycles for subfertile couples. Cochrane Database Syst Rev 1:CD003854
Cohen J (2003) Associated multiple gestation — ART. Clin Obstet Gynecol 46:363–374
Cohlen BJ (2005) Should we continue performing intrauterine inseminations in the year 2004? Gynecol Obstet Invest 59:3–13
Cohlen BJ, Vandekerckhove P, te Velde ER, Habbema JD (2000) Timed intercourse versus intra-uterine insemination with or without ovarian hyperstimulation for subfertility in men. Cochrane Database Syst Rev CD000360
Collins JA, Bustillo M, Visscher RD, Lawrence LD (1995) An estimate of the cost of in vitro fertilization services in the United States in 1995. Fertil Steril 64:538–545
Comhaire F, Milingos S, Liapi A, Gordts S, Campo R, Depypere H, Dhont M Schoonjans F (1994) The effective cumulative pregnancy rate of different modes of treatment of male infertility. Andrologia 27:217–221
Denschlag D, Tempfer C, Kunze M, Wolff G, Keck C (2004) Assisted reproductive techniques in patients with Klinefelter syndrome: a critical review. Fertil Steril 82:775–779
De Sutter P, Van der Elst J, Coetsier T, Dhont M (2003) Single embryo transfer and multiple pregnancy rate reduction in IVF/ICSI: a 5-year appraisal. Reprod Biomed Online 6: 464–469
Dhaliwal LK, Sialy RK, Gopalan S, Majumdar S (2002) Minimal stimulation protocol for use with intrauterine insemination in the treatment of infertility. J Obstet Gynaecol Res 28: 295–299
Evans MI, Berkowitz RL, Wapner RJ, Carpenter RJ, Goldberg JD, Ayoub MA, Horenstein J, Dommergues M, Brambati B, Nicolaides KH, Holzgreve W, Timor-Tritsch IE (2001) Improvement in outcomes of multifetal pregnancy reduction with increased experience. Am J Obstet Gynecol 184:97–103
Fauser BC, Bouchard P, Coelingh Bennink HJ, Collins JA, Devroey P, Evers JL, van Steirteghem A (2002) Alternative approaches in IVF. Hum Reprod Update 8:1–9
Fishel SB, Edwards RG (1982) Essentials of fertilisation. In: Edwards RG, Purdy JM (eds) Human conception in vitro. Academic Press, London, pp 157–179
Gerris J, De Neubourg D, Mangelschots K, Van Royen E, Van de Meerssche M, Valkenburg M (1999) Prevention of twin pregnancy after invitro fertilization or intracytoplasmic sperm injection based on strict embryo criteria: a prospective randomized clinical trial. Hum Reprod 14:2581–2587
Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V (2000) Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N Engl J Med 343:2–7
Goverde AJ, McDonnell J, Vermeiden JP, Schats R, Rutten FF, Schoemaker J (2000) Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomized trial and cost-effectiveness analysis. Lancet 355:13–18
Griffin M, Panak WF (1998) The economic cost of infertility related services: an examination of the Massachusetts infertility insurance mandate. Fertil Steril 70:22–29
Hohmann FP, Laven JS, de Jong FH, Eijkemans MJ, Fauser BC (2001) Lowdose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development. Hum Reprod 16:846–854
Hopps CV, Mielnik A, Goldstein M, Palermo GD, Rosenwaks Z, Schlegel PN (2003) Detection of sperm in men with Y chromosome microdeletions of the AZFa, AZFb and AZFc regions. Hum Reprod 18:1660–1665
Hughes EG, Giacomini M (2001) Funding in vitro fertilization treatment for persistent subfertility: the pain and the politics. Fertil Steril 76:431–442
Khalil MR, Rasmussen PE, Erb K, Laursen SB, Rex S, Westergaard LG (2001) Homologous intrauterine insemination. An evaluation of prognostic factors based on a review of 2473 cycles. Acta Obstet Gynecol Scand 80:74–81
Oehninger S, Acosta AA, Morshedi M, Veeck L, Swanson RJ, Simmons K, Rosenwaks Z (1988) Corrective measures and pregnancy outcome in in vitro fertilization in patients with severe sperm morphology abnormalities. Fertil Steril 50: 283–287
Ombelet W, Cox A, Janssen M, Vandeput H, Bosmans E (1996) Artificial insemination (AIH) artificial insemination 2: using the husband’s sperm. In: Acosta AA, Kruger TF (eds) Diagnosis and therapy of male factor in assisted reproduction. Parthenon, London, pp 397–410
Ombelet W, Vandeput H, Van de Putte G, Cox A, Janssen M, Jacobs P, Bosmans E, Steeno O, Kruger T (1997) Intrauterine insemination after ovarian stimulation with clomiphene citrate: predictive potential of inseminating motile count and sperm morphology. Hum Reprod 12:1458–1463
Ombelet W, Deblaere K, Bosmans E, Cox A, Jacobs P, Janssen M, Nijs M (2003) Semen quality and intrauterine insemination. Reprod Biomed Online 7:485–492
Ombelet W, De Sutter P, Van der Elst J, Martens G (2005) Multiple gestation and infertility treatment: registration, reflection and reaction—the Belgian project. Hum Reprod Update 11:3–14
Palermo G, Joris H, Devroey P, Van Steirteghem AC (1992) Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 340:17–18
Peterson CM, Hatasaka HH, Jones KP, Poulson AM Jr, Carrell DT, Urry RL (1994) Ovulation induction with gonadotropins and intrauterine insemination compared with in vitro fertilization and no therapy: a prospective, nonrandomized, cohort study and meta-analysis. Fertil Steril 62:535–544
Philips Z, Barraza-Llorens M, Posnett J (2000) Evaluation of the relative cost-effectiveness of treatments for infertility in the UK. Hum Reprod 15:95–106
Plosker SM, Jacobson W, Amato P (1994) Prediction and optimizing success in an intra-uterine insemination programme. Hum Reprod 9:2014–2021
Reijo R, Alagappan RK, Patrizio P, Page DC (1996) Severe oligozoospermia resulting from deletions of azoospermia factor gene on Y chromosome. Lancet 347:1290–1293
Reynolds MA, Schieve LA, Jeng G, Peterson HB (2003) Does insurance coverage decrease the risk for multiple births associated with assisted reproductive technology? Fertil Steril 80:16–23
Silber SJ, Nagy ZP, Liu J, Godoy H, Devroey P, Van Steirteghem AC (1994) Conventional in-vitro fertilization versus intracytoplasmic sperm injection for patients requiring microsurgical sperm aspiration. Hum Reprod 9:1705–1709
Sovino H, Sir-Petermann T, Devoto L (2002) Clomiphene citrate and oulation induction. Reprod Biomed Online 4:303–310
Stone J, Eddleman K, Lynch L, Berkowitz RL (2002) A single center experience with 1000 consecutive cases of multifetal pregnancy reduction. Am J Obstet Gynecol 187:1163–1167
Stovall DW, Allen BD, Sparks AET, Syrop CH, Saunders RG, Van Voorhis BJ (1999) The cost of infertility evaluation and therapy: findings of a self-insured university healthcare plan. Fertil Steril 72:778–784
Tiitinen A, Halttunen M., Härkki P, Vuoristo P, Hyden-Granskog C (2001) Elective single embryo transfer: the value of cryopreservation. Hum Reprod 16:1140–1144
Tiitinen A, Unkila-Kallio L, Halttunen M, Hyden-Granskog C (2003) Impact of elective single embryo transfer on the twin pregnancy rate. Hum Reprod 18:1449–1453
Tournaye H (1997) Use of testicular sperm for the treatment of male infertility. Baillieres Clin Obstet Gynaecol 11:753–762
Tournaye H, Devroey P, Liu J, Nagy Z, Lissens W, Van Steirteghem A (1994) Microsurgical epididymal sperm aspiration and intracytoplasmic sperm injection: a new effective approach to infertility as a result of congenital bilateral absence of the vas deferens. Fertil Steril 61:1045–1051
Tur R, Barri PN, Coroleu B, Buxaderas R, Martinez F, Balasch J (2001) Risk factors for high-order multiple implantation after ovarian stimulation with gonadotrophins: evidence from a large series of 1878 consecutive pregnancies in a single centre. Hum Reprod 16:2124–2129
Van Royen E, Mangelschots K, De Neubourg D, Valkenburg M, Van de Meerssche M, Ryckaert G, Eestermans W, Gerris J (1999) Characterization of a top quality embryo, a step towards single-embryo transfer. Hum Reprod 14:2345–2349
Van Voorhis BJ, Sparks AET, Allen BD, Stovall DW, Syrop CH, Chapler FK (1997) Cost-effectiveness of infertility treatments: a cohort study. Fertil Steril 67:830–836
Van Voorhis BJ, Barnett M, Sparks AET, Syrop CH, Rosenthal G, Dawson J (2001) Effect of the totile motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization. Fertil Steril 75:661–668
Van Waart J, Kruger TF, Lombard CJ, Ombelet W (2001) Predictive value of normal sperm morphology in intrauterine insemination (IUI): a structured literature review. Hum Reprod 7:495–500
Wolner-Hanssen P, Rydhstroem H (1998) Cost-effectiveness analysis of in-vitro fertilization: estimated costs per successful pregnancy after transfer of one or two embryos. Hum Reprod 13:88–94
Zayed F, Lenton EA, Cooke ID (1997) Comparison between stimulated in-vitro fertilization and stimulated intrauterine insemination for the treatment of unexplained and mild male factor infertility. Hum Reprod 12:2408–2413
Bibliografia
Agarwal A, Shekarriz M, Sidhu RK, Thomas AJ (1996) Value of clinical diagnosis in predicting the quality of cryopreserved sperm from cancer patients. J Urol 155:934–938
Agarwal A, Ranganathan P, Kattal N, Pasqualotto F, Hallak J, to be later available for ART. Khayal S, Mascha E (2004) Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril 81:342–348
Agca Y, Critser JK (2002) Cryopreservation of spermatozoa in assisted reproduction. Semin Reprod Med 20:15–23
Anger JT, Gilbert BR, Goldstein M (2003) Cryopreservation of sperm: indications, methods and results. J Urol 170:1079–1084
Bahadur G, Chatterjee R, Ralph D (2000) Testicular tissue cryopreservation in boys. Ethical and legal issues. Hum Reprod 15:1416–1420
Bell M, Wang R, Hellstrom WJG, Sikka SC (1993) Effect of cryoprotective additives and cryopreservation protocol on sperm membrane lipid peroxidation and recovery of motile human sperm. J Androl 14:472–478
Ben Rhouma K, Marrakchi H, Khouja H, Attalah K, Ben Miled E, Sakly M (2003) Outcome of intracytoplasmic injection of fresh and frozenthawed testicular spermatozoa. A comparative study. J Reprod Med 48:349–354
Blackmore PF, Neulen J, Lattanzio F, Beebe SJ (1991) Cell surface-binding sites for progesterone mediated calcium uptake in human sperm. J Biol Chem 266:18655–18659
Bongso A, Jarina AK, Ho J, Ng SC, Ratnam SS (1993) Comparative evaluation of three sperm-washing methods to improve sperm concentration and motility in frozen-thawed oligozoospermic and normozoospermic samples. Arch Androl 31:223–230
Brennan AP, Holden CA (1995) Pentoxifylline-supplemented cryoprotectant improves human sperm motility after cryopreservation. Hum Reprod 10:2308–2312
Brinster RL, Avarbock MR (1994) Germline transmission of donor haplotype following spermatogonial transplantation. Proc Natl Acad Sci USA 91:11303–11307
British Andrology Society (1999) British Andrology Society guidelines for the screening of semen donors for donor insemination (1999). Hum Reprod 14:1823–1826
Brotherton J (1990) Cryopreservation of human semen. Arch Androl 25:181–195
Brougham MF, Kelnar CJ, Sharpe RM, Wallace WH (2003) Male fertility following childhood cancer: current concepts and future therapies. Asian J Androl 5:325–337
Centola GM, Raubertas RF, Mattox JH (1992) Cryopreservation of human semen. Comparison of cryopreservatives, sources of variability, and prediction of post-thaw survival. J Androl 13:283–288
Centola GM, Cartie RJ, Cox C (1995) Differential response of human sperm to varying concentrations of pentoxifylline with demonstration of toxicity. J Androl 16:136–142
Chan CC, Chen IC, Liu JY, Huang YC, Wu GJ (2004) Comparison of nitric oxide production motion characteristics of sperm after cryopreserved in three different preparations. Arch Androl 50:1–3
Chan SYW, Craft IL, Chan YM, Leong MKH, Leung CKM (1990) The hypoosmotic swelling test and cryosurvival of human spermatozoa. Hum Reprod 5:715–718
Chohan KR, Griffin JT, Carrell DT (2004) Evaluation of chromatin integrity in human sperm using acridine orange staining with different fixatives and after cryopreservation. Andrologia 36:321–326
Chung K, Irani J, Knee G, Efymow B, Blasco L, Patrizio P (2004) Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur J Obstet Gynecol Reprod Biol 113 (Suppl. 1):S7–S11
Clarke GN (1999) Sperm cryopreservation: is there a significant risk of cross-contamination? Hum Reprod 14:2941–2943
Critser JK, Huse-Benda AR, Aaker DV, Arneson BW, Ball GD (1988) Cryopreservation of human spermatozoa. III. The effect of cryoprotectants on motility. Fertil Steril 50:314–320
Cross NL, Hanks SE (1991) Effects of cryopreservation on human sperm acrosomes. Hum Reprod 6:1279–1283
De Jonge CJ, Han HL, Lawrie H, Mack SR, Zaneveld LJD (1991) Modulation of the human sperm acrosome reaction by effectors of the adenylate cyclase/cyclic AMP second-messenger pathway. J Exp Zool 258:113–125
Donnelly ET, Steele EK, McClure N, Lewis SE (2001) Assessment of DNA integrity and morphology of ejaculated spermatozoa from fertile and infertile men before and after cryopreservation. Hum Reprod 16:1191–1199
Esteves SC, Sharma RK, Thomas AJ, Agarwal A (1996) Suitability of the hypo-osmotic swelling test for assessing the viability of cryopreserved sperm. Fertil Steril 66:798–804
Esteves SC, Sharma RK, Thomas AJ Jr, Agarwal A (2000) Improvement in motion characteristics and acrosome status in cryopreserved human spermatozoa by swim-up processing before freezing. Hum Reprod 15:2173–2179
Fisch JD, Behr B, Conti M (1998) Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by typespecific phosphodiesterase inhibitors. Hum Reprod 13:1248–1254
Frederickx V, Michiels A, Goossens E, De Block G, Van Steirteghem AC, Tournaye H (2004) Recovery, survival and functional evaluation by transplantation of frozen-thawed mouse germ cells. Hum Reprod 19:948–953
Gamzu R, Yogev L, Yavetz H, Homonnai ZT, Hiss Y, Paz G (1992) Fresh and frozen-thawed human sperm bind in a similar pattern to the zona pellucida in the hemizona assay. Fertil Steril 58:1254–1256
Gilmore JA, Liu J, Gao DY, Critser JK (1997) Determination of optimal cryoprotectants and procedures for their addition and removal from human spermatozoa. Hum Reprod 12:112–118
Goossens E, Frederickx V, De Block G, Van Steirteghem AC, Tournaye H (2003) Reproductive capacity of sperm obtained after germ cell transplantation in a mouse model. Hum Reprod 18:1874–1880
Hallak J, Sharma RK, Thomas AJ, Agarwal A (1998) Why cancer patients request disposal of cryopreserved semen specimens posttherapy: a retrospective study. Fertil Steril 69:889–893
Hammadeh ME, Georg T, Rosenbaum P, Schmidt W (2001a) Association between freezing agent and acrosome damage of human spermatozoa from subnormal and normal semen. Andrologia 33:331–336
Hammadeh ME, Greiner S, Rosenbaum P, Schmidt W (2001b) Comparison between human sperm preservation medium and TEST-yolk buffer on protecting chromatin and morphology integrity of human spermatozoa in fertile and subfertile men after freeze-thawing procedure. J Androl 22:1012–1018
Hammerstedt RH, Graham JK, Nolan JP (1990) Cryopreservation of mammalian sperm: what we ask them to survive. J Androl 11:73–88
Holland-Moritz H, Krause W (1990) Use of cryopreservation by tumor patients. Hautarzt 41:204–206
Hovatta O (2003) Cryobiology of ovarian and testicular tissue. Best Pract Res Clin Obstet Gynaecol 17:331–342
Hsieh YY, Tsai HD, Chang CC, Lo HY (2000) Cryopreservation of human spermatozoa within human or mouse empty zonae pellucidae. Fertil Steril 73:694–698
Kamischke A, Jurgens H, Hertle L, Berdel WE, Nieschlag E (2004) Cryopreservation of sperm from adolescents and adults with malignancies. J Androl 25:586–592
Kaneko S, Kobayashi T, Lee HK, Won WK, Oda T, Izumi Y, Ohono T, Iizuka R (1990) Cryogenic preservation of lowquality human semen. Arch Androl 24:81–86
Keck C, Nieschlag E (1993) Cryopreservation of spermatozoa and its importance in the management of malignant diseases. Fertilität 9:145–151
Khalifa E, Oehninger S, Acosta AA, Morshedi M, Veeck L, Bryzyski RG, Muasher SJ (1992) Successful fertilization and pregnancy outcome in in-vitro fertilization during cryopreserved/thawed spermatozoa from patients with malignant diseases. Hum Reprod 7:105–108
Köhn FM, Schill W-B (1988) The Munich cryopreserved sperm bank — intermediate 1974-1986 evaluation. Hautarzt 39: 91–96
Köhn FM, Volk R, Schill WB (1997) Cryopreservation of semen samples from severely oligozoospermic men. Hum Reprod 12 (Abstract Book 1):237
Köhn FM, Schroeder-Printzen I, Weidner W, Montag M, van der Ven H, Schill WB (2001) Testicular sperm extraction in a patient with metachronous bilateral testicular cancer. Hum Reprod 1:2343–2346
Krause W, Brake A (1994) Utilization of cryopreserved semen in tumor patients. Urol Int 52:65–68
Lacham-Kaplan O, Trounson A (1993) The effects of the sperm motility activators 2-deoxyadenosine and pentoxifylline used for sperm microinjection on mouse and human embryo development. Hum Reprod 6:945–952
Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP (1997) Fertility after chemotherapy for testicular germ cell cancers. Clin Oncol 15:239–245
Linden JV, Centola G (1997) New American Association of Tissue Banks standards for semen banking. Fertil Steril 68:597–600
Mack SR, Zaneveld JD (1987) Acrosomal enzymes and ultrastructure of unfrozen and cryotreated human spermatozoa. Gamete Res 18:375–383
Mahadevan MM, Trounson AO, Leeton JF (1983) Successful use of human semen cryobanking for in vitro fertilization. Fertil Steril 40:340–343
Mayaux MJ, Schwartz E, Czyalik F, David G (1985) Conception rate according to semen characteristics in a series of 15,364 insemination cycles: results of a multivariate analysis. Andrologia 17:9–15
Mbizvo MT, Johnston RC, Baker GHW (1993) The effect of the motility stimulants, caffeine, pentoxifylline, and 2-deoxyadenosine on hyperactivation of cryopreserved human sperm. Fertil Steril 59:1112–1117
McLaughlin EA, Ford WCL, Hull MGR (1992) Motility characteristics and membrane integrity of cryopreserved human spermatozoa. J Reprod Fertil 95:527–534
Merino G, Martinez Chéquer JC, Barahona E, Bermùdez JA, Morán C, Carranza-Lira S (1997) Effects of pentoxifylline on sperm motility in normogonadotropic asthenozoospermic men. Arch Androl 39:65–69
Meseguer M, Garrido N, Remohi J, Pellicer A, Simon C, Martinez-Jabaloyas JM, Gil-Salom M (2003) Testicular sperm extraction (TESE) and ICSI in patients with permanent azoospermia after chemotherapy. Hum Reprod 18:1281–1285
Meseguer M, Garrido N, Martinez-Conejero JA, Simon C, Pellicer A, Remohi J (2004) Role of cholesterol, calcium, and mitochondrial activity in the susceptibility for cryodamage after a cycle of freezing and thawing. Fertil Steril 81:588–594
Nassar A, Mahony M, Blackmore P, Morshedi M, Ozgur K, Oehninger S (1998) Increase of intracellular calcium is not a cause of pentoxifylline-induced hyperactivated motility or acrosome reaction in human sperm. Fertil Steril 69:748–754
Nordhoff V, Schlatt S (2003) Present and future options for the preservation of testis tissue and function. Endocr Dev 5:136–155
O’Connell M, McClure N, Lewis SE (2002) The effects of cryopreservation on sperm morphology, motility and mitochondrial function. Hum Reprod 17:704–709
O’Donnell JM (2000) William Harvey Research Conference on PDE inhibitors: drugs with an expanding range of therapeutic uses. Expert Opin Investig Drugs 9:621–625
Padron OF, Sharma RK, Thomas AJ Jr, Agarwal A (1997) Effects of cancer on spermatozoa quality after cryopreservation: a 12-year experience. Fertil Steril 67:326–331
Paul M, Sumpter JP, Lindsay KS (1996) The paradoxical effects of pentoxifylline on the binding of spermatozoa to the human zona pellucida. Hum Reprod 11:814–819
Payne MA, Lamb EJ (2004) Use of frozen semen to avoid human immunodeficiency virus type 1 transmission by donor insemination: a cost-effectiveness analysis. Fertil Steril 81:80–92
Pérez-Sànchez E, Cooper TG, Yeung CH, Nieschlag E (1994) Improvement in quality of cryopreserved human spermatozoa by swim-up before freezing. Int J Androl 17:115–120
Quinn P (1993) Cryopreservation. In: Marrs RP (ed) Assisted reproductive technologies. Blackwell, Oxford, pp 89
Rubio C, Minguez Y, Ruis A, Amorocho B, Romero J, De los Santos MJ (1996) Efficacy of sperm cryopreservation of ejaculated, testicular and epididymal spermatozoa for ICSI. Hum Reprod 11 (Abstract Book 1):89
Schill WB (1975) Acrosin activity of cryopreserved human spermatozoa. Fertil Steril 26:711–720
Schill WB (1986) Established and new approaches in medical treatment of male sterility. Fertilität 2:7–17
Schill WB, Bollmann W (1986) Semen preservation, insemination, in vitro fertilization. Urban and Schwarzenberg, Munich
Schill WB, Köhn FM (1997) Cryobanking of spermatozoa: is there a continuing need for semen cryopreservation? In: Waites GMH, Frick J, Baker GWH (eds) Current advances in andrology. Monduzzi Editore, Bologna, pp 371–382
Schill WB, Pritsch W, Preissler G (1979) Effect of caffeine and kallikrein on cryo-preserved human spermatozoa. Int J Fertil 24:27–32
Schill WB, Töpfer-Petersen E, Hoffmann R, Michalopoulos M, Rübekeil A (1986) Untersuchungen zur Schädigung von Kryosperma. In: Schill WB, Bollmann W (eds) Spermakonservierung, Insemination, In-vitro-fertilisation. Urban and Schwarzenberg, Munich, pp 35
Schrader M, Muller M, Sofikitis N, Straub B, Krause H, Miller K (2003) “Onco-tese”: testicular sperm extraction in azoospermic cancer patients before chemotherapy-new guidelines? Urology 61:421–425
Schuster TG, Keller LM, Dunn RL, Ohl DA, Smith GD (2003) Ultrarapid freezing of very low numbers of sperm using cryoloops. Hum Reprod 18:788–795
Serafini PC, Hauser D, Moyer D, Marrs RP (1986) Cryopreservation of human spermatozoa: correlations of ultrastructural sperm head configuration with sperm motility and ability to penetrate zonafree hamster ova. Fertil Steril 46:691–695
Sharma RK, Tolentino MV, Thomas AJ, Agarwal A (1996) Optimal dose and duration of exposure to artificial stimulants in cryopreserved human spermatozoa. J Urol 155:568–573
Sherman JK (1986) Current status of clinical cryobanking of human semen. In: Paulson JD, Negro-Vilar A, Lucena E, Martini L (eds) Andrology, male fertility and sterility. Academic Press, Orlando, pp 517
Stanic P, Sonicki Z, Suchanek E (2002) Effect of pentoxifylline on motility and membrane integity of cryopreserved human spermatozoa. Int J Androl 25:186–190
Stewart GJ, Tyler JP, Cunningham AL, Barr JA, Driscoll GL, Gold J, Lamont BJ (1985) Transmission of human T-cell lymphotropic virus type III (HTLV-III) by artificial insemination by donor. Lancet 2:581–585
Terriou P, Hans E, Giorgetti C, Spach JL, Salzmann J, Urrutia V, Roulier R (2000) Pentoxifylline initiates motility in spontaneously immotile epididymal and testicular spermatozoa and allows normal fertilization, pregnancy, and birth after intracytoplasmic sperm injection. J Assist Reprod Genet 17:194–199
Tesarik J, Mendoza C, Carreras A (1992) Effects of phosphodiesterase inhibitors caffeine and pentoxifylline on spontaneous and stimulus-induced acrosome reaction in human sperm. Fertil Steril 58:1185–1189
Tournaye H, Van der Linden M, Van den Abbeel E, Devroey P, Van Steirteghem A (1993a) Effects of pentoxifylline on invitro development of preimplantation mouse embryos. Hum Reprod 8:1475–1480
Tournaye H, Van der Linden M, Van den Abbeel E, Devroey P, Van Steirteghem A (1993b) Effects of pentoxifylline on implantation and post-implantation development of mouse embryos in vitro. Hum Reprod 8:1948–1954
Tournaye H, Devroey P, Camus M, Van der Linden M, Janssens R, Van Steirteghem A (1995) Use of pentoxifylline in assisted reproductive technology. Hum Reprod 10:72–79
Tournaye H, Goossens E, Verheyen G, Frederickx V, De Block G, Devroey P, Van Steirteghem A (2004) Preserving the reproductive potential of men and boys with cancer: current concepts and future prospects. Hum Reprod Update 10:525–532
Trounson AO, Conti A (1982) Research in human in vitro fertilization and embryo transfer. Br Med J (Clin Res Ed) 285: 244–248
Van der Elst J, Verheyen G, Van Steirteghem A (1997) Cryopreservation: sperms and oocytes. In: Rabe T, Diedrich K, Runnebaum B (eds) Manual on assisted reproduction. Springer, Berlin Heidelberg New York, pp 223
Wood S, Thomas K, Schnauffer K, Troup S, Kingsland C, LewisJones I (2002) Reproductive potential of fresh and cryopreserved epididymal and testicular spermatozoa in consecutive intracytoplasmic sperm injection cycles in the same patients. Fertil Steril 77:1162–1166
Wood S, Sephton V, Searle T, Thomas K, Schnauffer K, Troup S, Kingsland C, Lewis-Jones I (2003) Effect on clinical outcome of the interval between collection of epididymal and testicular spermatozoa and intracytoplasmic sperm injection in obstructive azoospermia. J Androl 24:67–72
Yavetz H, Yogev L, Homonnai Z, Paz G (1991) Prerequisites for successful human sperm cryobanking: sperm quality and prefreezing holding time. Fertil Steril 55:812–816
Yogev L, Gamzu R, Botchan A, Homonnai ZT, Amit A, Lessing JB, Paz G, Yavetz H (1995) Pentoxifylline improves sperm binding to the zona pellucida in the hemizona assay. Fertil Steril 64:146–149
Yogev L, Gamzu R, Botchan A, Hauser R, Paz G, Yavetz H (2000) Zona pellucida binding improvement effect of different sperm preparation techniques is not related to changes in sperm motility characteristics. Fertil Steril 73:1120–1125
Zhang Z, Renfree MB, Short RV (2003) Successful intra-and interspecific male germ cell transplantation in the rat. Biol Reprod 68:961–967
Bibliografia
Aguilar LK, Aguilar-Cordova E (2003) Evolution of a gene therapy clinical trial. From bench to bedside and back. J Neurooncol 65:307–315
Baum BJ et al (2003) Advances in vector-mediated gene transfer. Immunol Lett 90:145–149
Belldegrun A et al (2001) Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 12:883–892
Bivalacqua TJ (2000) Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age related erectile dysfunction in the rat. Int J Impot Res 12 [Suppl 3]:S8–S17
Bivalacqua TJ et al (2001) Gene transfer of prepro-calcitonin gene-related peptide restores erectile function in the aged rat. Biol Reprod 65:1371–1377
Bivalacqua TJ et al (2003) Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 169:1911–1917
Champion HC et al (1999) Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci USA 96:11648–11652
Chancellor MB et al (2003) Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int 91:691–696
Christ GJ (2002) K channels as molecular targets for the treatment of erectile dysfunction. J Androl 23:S10–S19
Christ G J (2003) Frontiers in gene therapy for erectile dysfunction. Int J Impot Res Suppl 5:S33–S40
Christ GJ et al (1998) Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol 275:H600–H608
Collins SJ et al (2003) Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy. World J Urol 2:275–289
Cram DS et al (2001) Male infertility genetics-the future. J Androl 22:738–746
Crystal RG (1995) Transfer of genes to humans: early lessons and obstacles to success. Science 270:404–410
De Jonge CJ, Barratt CL (2002) The future of reproductive cellular engineering in male infertility. Urol Clin North Am 29:809–815
DeWeese TL et al (2001) A phase I trial of CV706, a replication competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61:7464–7472
Foley R et al (2004) Gene-based therapy in prostate cancer. Lancet Oncol 5:469–479
Freytag SO et al (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62:4968–4976
Garban H (1997) Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod 56:954–963
Garrison JB, Kyprianou N (2004) Novel targeting of apoptosis pathways for prostate cancer therapy. Curr Cancer Drug Targets 4:85–95
Gholami SS et al (2003) The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol 169:1577–1581
Gonzalez-Cadavid NF, Rajfer J (2004) Therapy of erectile dysfunction: potential future treatments. Endocrine 23:167–176
Hargreave TB (2000) Genetic basis of male infertility. Br Med Bull 56:650–671
Ikawa M et al (2002) Restoration of spermatogenesis by lentiviral gene transfer: offspring from infertile mice. Proc Natl Acad Sci USA 99:7524–7529
Kanatsu-Shinohara M (2002) Adenovirus-mediated gene delivery and in vitro microinsemination produce offspring from infertile male mice. Proc Natl Acad Sci USA 99: 1383–1388
Kojima Y et al (2003) Effects of adenovirus mediated gene transfer to mouse testis in vivo on spermatogenesis and next generation. J Urol 170:2109–2114
Lundstrom K, Boulikas T (2003) Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat 2:471–486
Mabjeesh NJ et al (2002) Gene therapy of prostate cancer: current and future directions. Endocr Relat Cancer 9:115–139
Magee TR et al (2002) Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 67:1033–1041
Maitland NJ et al (2004) Targeting gene therapy for prostate cancer. Curr Pharm Des 10:531–555
Mazhar D, Waxman J (2004) Gene therapy for prostate cancer. BJU Int 93:465–469
Miles BJ et al (2001) Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12:1955–1967
Nagano M et al (2001) Transgenic mice produced by retroviral transduction of male germ-line stem cells. Proc Natl Acad Sci USA 98:111–115
Nakamori M et al (2004) Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 60:53–60
Ratko TA et al (2003) Clinical gene therapy for nonmalignant disease. Am J Med 115:560–5699
Sato M et al (2002) Direct injection of foreign DNA into mouse testis as a possible in vivo gene transfer system via epididymal spermatozoa. Mol Reprod Dev 61:49–56
Schenk G et al (2001) Gene therapy: future therapy for erectile dysfunction. Curr Urol Rep 2:480–487
Seftel A (2003) Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy and reverse venogenic erectile dysfunction in rats. J Urol 170:681
Smith KR (2003) Gene therapy: theoretical and bioethical concepts. Arch Med Res 34:247–268
Spink J (2004) Gene therapy progress and prospects: bringing gene therapy into medical practice: the evolution of international ethics and the regulatory environment. Gene Ther 11:1611–1616
Steiner MS, Gingrich JR (2000) Gene therapy for prostate cancer: where are we now? J Urol 164:1121–1136
Tirney S et al (2001) Nitric oxide synthase gene therapy for erectile dysfunction: comparison of plasmid, adenovirus, and adenovirustransduced myoblast vectors. Mol Urol 5:37–43
Umemoto Y et al (2005) Gene transfer to mouse testes by electroporation and its influence on spermatogenesis. J Androl 26:264–271
Yomogida K et al (2002) Electroporated transgene-rescued spermatogenesis in infertile mutant mice with a Sertoli cell defect. Biol Reprod 67:712–717
Bibliografia
Aass N, Grunfeld B, Kaalhus O, Fossa SD (1993) Pre-and post-treatment sexual life in testicular cancer patients: a descriptive investigation. Br J Cancer 67:1113–1117
American Psychiatric Association (1996) Diagnostic and statistical manual of mental disorders, III edn. American Psychiatric Association, Washington
Andersen BL (1990) How cancer affects sexual functioning. Oncology 4:81–94
Baker DI, Shutte JL, Unlamann WR (1998) A guide to genetic counselling. Wiley, New York
Bancroft J (1999) Sexual science in the 21st century: where are we going? A personal note. J Sex Res 36:226–229
Barnes T (1999) Integrated sex therapy: the interplay of behavioral, cognitive and medical approaches. In: Carson CC, Kirby ES, Goldstein I (eds) Textbook of erectile dysfunction. Isis Medical, Oxford, pp 465–484
Boivin J, Kentenich H (2002) Guidelines for counselling in infertility. ESHRE Monographs [Hum Reprod J Series]. Oxford University Press, Oxford
Brown GR (1990) A review of clinical approaches to gender dysphoria. J Clin Psychiatr 51:57–64
Burns LH, Covington SN (1999) Infertility counselling: a comprehensive handbook for clinicians. Parthenon, New York, pp 152
Carroll RA (2000) Assessment of gender dysphoria. In: Leiblum SR, Rosen RC (eds) Principles and practice of sex therapy, III edn. Guilford, New York, pp 368–397
De Gennaro L, Balistreri S, Lenzi A, Lombardo F, Ferrara M, Gandini L (2003) Psychosocial factors discriminate oligozoospermic from normozoospermic men. Fertil Steril 79:1571–1576
Dengrove E (1967) Behavior therapy for the sexual disorders. J Sex Res 3:49–61
Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB (2000) Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 56:302–306
Dohle GR, Halley DJ, Van Hemel JO, van den Ouwel AM, Pieters MH, Weber RF, Govaerts LC (2002) Genetic risk factors in infertile men with severe oligozoospermia and azoospermia. Hum Reprod 17:13–16
Dunn ME (2004) Restoration of couple’s intimacy and relationship ship vital to re-establishing erectile function. J Am Osteopath Assoc 104 [3 Suppl 4]:S6–S10
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts male Aging Study. J Urol 151:54–60
Figa-Talamanca I, Cini C, Varricchio GC, Dondero F, Gandini L, Lenzi A, Lombardo F, Angelucci L, Di Grezia R, Patacchioli FR (1996) Effects of prolonged autovehicle driving on male reproductive function: a study among taxi drivers. Am J Ind Med 30:750
Gandini L, Lombardo F, Salacone P, Paoli D, Anselmo AP, Culasso F, Dondero F, Lenzi A (2003) Testicular cancer and Hodgkin’s disease: evaluation of semen quality. Human Reprod 18:796–801
Given C, Given B, Rahbar M, Jeon S, McCorkle R, Cimprich B, Galecki A, Kozachik S, Brady A, Fisher-Malloy MJ, Courtney K, Bowie E (2004) Effect of behavioural intervention on reducing symptom severity during chemotherapy. J Clin Oncol 22:507–516
Giwercman A (2003) Gonadotoxic cancer treatment in males-a reason for andrological counselling? Radiother Oncol 68:213–215
Heidenreich A, Hofmann R (1999) Quality-of-life issues in the treatment of testicular cancer. World J Urol 17:230–238
Henry Benjamin International Gender Dysphoria Association (1998) The standards of care of gender identity disorders. Düsseldorf, Symposium, p 22
Jannini EA, Lenzi A (2003) Introduction to the integrated model: medical, surgical and psychological therapies for the couple. J Endocrinol Invest 26 [Suppl 3]:128–131
Jannini EA, Simonelli C, Lenzi A (2002a) Sexological approach to ejaculatory disorders. Int J Androl 25:317–323
Jannini EA, Simonelli C, Lenzi A (2002b) Disorders of ejaculation. J Endocrinol Invest 25:1006–1019
Jannini EA, Lenzi A, Wagner G (2003a) New perspectives in the pharmacotherapy of erectile dysfunction. IDrugs 6:1165–1172
Jannini EA, Lombardo F, Salacone P, Gandini L, Lenzi A (2003b) Treatment of sexual dysfunctions secondary to male infertility with sildenafil citrate. Fertil Steril 81:705–707
Jiann BP, Yu CC, Su CC, Huang JK (2004) Rechallenge prior sildenafil nonresponders. Int J Impot Res 16:64–68
Kaplan HS (1974) The new sex therapy: active treatment of sexual dysfunction. Brunner/Mazel, New York
Kessler S (1997) Psychological aspects of genetic counselling. Am J Med Gen 72:164–171
Kruijver FPM, Zhou J-N, Pool CW, Hofman MA, Gooren LJG, Swaab DF (2000) Male-to-female transsexuals have female neuron numbers in a limbic nucleus. J Clin Endocrinol Metab 85:2034–2041
Leiblum SR, Rosen RC (2000) Sex therapy in the age of Viagra. In: Leiblum SR, Rosen RC (eds) Principles and practice of sex therapy, III edn. Guilford, New York, pp 1–13
Lenzi A (1995) Male infertility: evaluation of human sperm function and its clinical application. J Endocrinol Invest 18:468–488
Lenzi A (2003) The role of the medical andrologist in the assisted reproduction era. J Endocrinol Invest 26:268–273
Lenzi A, Lombardo F, Salacone P, Gandini L, Jannini EA (2003) Stress, sexual dysfunctions, and male infertily. J Endocrinol Invest, 26 [Suppl 3]:72–76
Masters WH, Johnson VE (1970) Human sexual inadequacy. Little Brown, Boston, Mass.
McCarthy BW (1989) Cognitive-behavioral strategies and techniques in the treatment of early ejaculation. I: Leiblum SR, Rosen RC (eds) Principles and practice of sex therapy-update for the 1990s, 2nd edn. Guilford, New York, pp 141–167
McDowell AJ, Snellgrove CA, Bond MJ (2001) Beyond Viagra. Psychological issues in the assessment and treatment of erectile dysfunction. Aust Fam Physician 30:867–873
Meyer JM (1979) The theory of gender identity disorders. J Am Psychoanal Assoc 30:381–418
Michie S, Marteau TM, Bobrow M (1997) Genetic counseling. The psychological impact of meeting patient’s expectations. J Med Gen 34:237–241
Montie JE (1994) Counseling the patient with localized prostate cancer. Urology 43 [Suppl 2]:36–40
Moreira E, Glasser DB, Laumann E, Nicolosi A, Brock G, Gingell C for the GSSAB Investigators’ Group (2003) Help-seeking behavior for sexual problems according to gender: results from the global survey of sexual attitudes and behaviors. Proceeding of the VII Latin American Congress for the Study of Impotence and Sexuality, Cartagena, Colombia
Nap AW, Van Golde RJT, Tuerlings JHAM, De Sutter P, Pieters MHEC, Giltay JC, Kastrop PMM, Braat DDM, Kremer JAM (1999) Reproductive decisions of men with microdeletions of the Y chromosome: the role of genetic counselling. Hum Reprod 14:2166–2169
Perelman MA (2003) Sex coaching for physicians: combination treatment for patients and partner. Int J Impot Res 15 [Suppl 5]:S-7–S74
Petrone L, Mannucci E, Corona G, Bartolini M, Forti G, Giommi G, Maggi M (2003) Structure interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 15:210–220
Phadke SR (2004) Genetic counselling. Indian J Pediatr 71:151–156
Pinchera A, Jannini EA, Lenzi A (2003) Research and academic education in medical sexology. J Endocrinol Invest 26 [Suppl 3]:13–14
Rosen RC (2001) Psychogenic erectile dysfunction. Urol Clin North Am 28:269–278
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830
Sachs BD (2000) Contextual approaches to the physiology and classification of erectile function, erectile dysfunction, and sexual arousal. Neurosci Biobehav Rev 24:541–560
Sachs BD (2003) The false organic-psychogenic distinction and related problems in the classification of erectile dysfunction. Int J Impot Res 15:72–78
Seftel AD, Althof SE (1997) Premature ejaculation. In: Mulcahy JJ (ed) Diagnosis and management of male sexual dysfunction. Igaku-Shoin, New York, pp 196–203
Shover L, Leiblum S (1994) The stagnation of sex therapy. J Psychol Human Sexuality 6:5–10
Stotts RC (2004) Cancers of prostate, penis, and testicles: epidemiology, prevention, and treatment. Nurs Clin North Am 39:327–340
Sundquist K (2003) Sexuality and body image after cancer. Aust Fam Physician 32:19–22
Von Eschembach AC, Schover LR (1984) The role of sexual rehabilitation in the treatment of patients with cancer. Cancer 54:2662–2667
Wagner G, Green R (1981) Impotence-physiological, psychological, surgical diagnosis and treatment. Plenum, New York
Wagner G, Kaplan HS (1993) The new injection treatment for impotence. Medical and psychological aspects. Brunner and Mazel, New York
Wagner G, Fugl-Meyer KS, Fugl-Meyer AR (2000) Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 12 [Suppl 4]:S144–S146
Wagner G, Claes H, Costa P, Cricelli C, De Boer J, Debruyne FM, Dean J, Dinsmore WW, Fitzpatrick JM, Ralph DJ, Hakkett GI, Heaton JP, Hatzichristou DG, Mendive J, Meuleman EJ, Mirone V, Montorsi F, Raineri F, Schulman CC, Stief CG, Von Keitz AT, Wright PJ, Lygon Arms Group (2002) A shared care approach to the management of erectile dysfunction in the community. Int J Impot Res 14:189–194
Bibliografia
Asch RH, Balmaceda JP, Ellsworth LR, Wong PC (1986) Preliminary experiences with gamete intrafallopian transfer (GIFT). Fertil Steril 45:366–371
Asche R, Balmaceda J, Ord T, Borrero C, Cefalu E, Gastaldi C, Rojas F (1987) Oocyte donation and gamete intrafallopian transfer as treatment for premature ovarian failure. Lancet i:687
Baker HW, Bangah ML, Burger HG, Kovacs GT, Summerbell D, Warnes GM (1986) Timing of ovulation by determination of the urinary luteinizing hormone surge with an enzymelinked monoclonal antibody dipstick (OvuStick). Aust N Z J Obstet Gynaecol 26:79–83
Bangsboll S, Pinborg A, Yding Andersen C, Nyboe Andersen A (2004) Patients’ attitudes towards donation of surplus cryopreserved embryos for treatment or research. Hum Reprod 19:2415–2419
Behrman SJ (1959) Artificial insemination. Fertil Steril 10:248–258
Billings JJ (1972) Ovulation method of family planning. Lancet 2:1193–1194
Borini A, Bonu MA, Coticchio G, Bianchi V, Cattoli M, Flamigni C (2004) Pregnancies and births after oocyte cryopreservation. Fertil Steril 82:601–605
Bryant J, Sullivan E, Dean J (2004) Assisted reproductive technology in Australia and New Zealand 2002. Assisted Reproductive Technology Series No. 8. Australian Institute of Health and Welfare National Perinatal Statistics Unit, Sydney
Bunge RG, Keettel WC, Sherman JK (1954) Clinical use of frozen semen: report of four cases. Fertil Steril 5:520–529
Burton PJ, Sanders K (2004) Patient attitudes to donation of embryos for research in Western Australia. Med J Aust 180:559–561
Cattoli M, Borini A, Bonu MA (2004) Fate of stored embryos: our 10 years experience. Eur J Obstet Gynecol Reprod Biol 115 [Suppl 1]: S16–S18
Chan CL, Kumar J, Ong ML, Ng SC, Bongso TA, Ratnam SS (1996) The first frozen embryo donation pregnancy for hypergonadotrophic hypogonadism in Singapore — hormonal profile and obstetric outcome. Med J Malaysia 51:482–484
Chan R, Raboy B, Patterson C (1998) Psychosocial adjustment among children conceived via donor insemination by lesbian and heterosexual mothers. Child Dev 69:443–457
Clayton CE, Kovacs GT (1980) A.I.D. — a pretreatment social assessment. Aust N Z J Obstet Gynaecol 20:208–210
Clayton CE, Kovacs GT (1982) AID offspring: initial follow-up study of 50 couples. Med J Aust 1:338–339
Cook R, Golombok S, Bish A, Murray C (1995) Disclosure of donor insemination: parental attitudes. Am J Orthopsychiatry 65:549–559
deKretser D, Yates C, Kovacs G (1986) The use of in vitro fertilization in the management of male infertility. Clin Obstet Gynecol 12:767–773
Devroey P, Camus M, van den Abbeel E, van Waesberghe L, Wisanto A, van Steirteghem AC (1989) Establishment of 22 pregnancies after oocyte and embryo donation. Br J Obstet Gynaecol 96:900–906
Dixon RE, Buttram VC (1976) Artificial insemination using donor semen: a review of 171 cases. Fertil Steril 27:130–134
Durna EM, Bebe J, Steigrad SJ, Leader LR, Garrett DG (1997) Donor insemination: attitudes of parents towards disclosure. Med J Aust 167:256–259
Edwards RG, Steptoe PC (1975) Induction of follicular growth, ovulation and luteinization in the human ovary. J Reprod Fertil Suppl 22:121–163
Elkind-Hirsch K, Goldzieher JW, Gibbons WE, Besch PK (1986) Evaluation of the OvuSTICK urinary luteinizing hormone kit in normal and stimulated menstrual cycles. Obstet Gynecol 67:450–453
Fabregues F, Balasch J, Creus M, Civico S, Carmona F, Puerto B, Vanrell JA (1998) Long-term down-regulation does not improve pregnancy rates in an in vitro fertilization program. Fertil Steril 70:46–51
Feichtinger W, Kemeter P (1985) Pregnancy after total ovarioectomy achieved by ovum donation. Lancet ii:722–723
Fortescue E (2003) Gamete donation — where is the evidence that there are benefits in removing the anonymity of donors? A patient’s viewpoint. Reprod Biomed Online 7:139–144
Geijsen N, Horoschak M, Kim K, Gribnau J, Eggan K, Daley GQ (2004) Derivation of embryonic germ cells and male gametes from embryonic stem cells. Nature 427:148–154
Golombok S, MacCallum F, Goodman E, Rutter M (2002) Families with children conceived by donor insemination: a follow-up at age twelve. Child Dev 73:952–968
Hill AM (1970) Experiences with artificial insemination. Aust N Z J Obstet Gynaecol 10:112–114
Hoy J, Venn A, Halliday J, Kovacs G, Waalwyk K (1999) Perinatal and obstetric outcomes of donor insemination using cryopreserved semen in Victoria, Australia. Hum Reprod 14:1760–1764
Huang JC, Jackson KV, Hornstein MD, Ginsburg ES (1996) The effect of elevated serum progesterone during ovulation induction in in vitro fertilization-embryo transfer. J Assist Reprod Genet 13:617–624
Hubner K, Fuhrmann G, Christenson LK, Kehler J, Reinbold R, De La Fuente R, Wood J, Strauss JF, 3rd, Boiani M, Scholer HR (2003) Derivation of oocytes from mouse embryonic stem cells. Science 300:1251–1256
Jequier A (2000) Male infertility: a guide for the clinician. Blackwell Science, Oxford
King C, Kovacs G (1992) Oocyte donation: review of results. In: Oocyte donation. Reprod Fertil Dev 4:60719–60724
Kleegman SJ (1954) Therapeutic donor insemination. Fertil Steril 5:7–31
Kovacs GT, King C (1994) The use of gamete intra-fallopian transfer with donor spermatozoa after failed donor insemination. Hum Reprod 9:859–860
Kovacs GT, Lording DW (1980) Artificial insemination with donor semen. Review of 252 patients. Med J Aust 2:609–612
Kovacs GT, Leeton JF, Matthews CD, Steigrad SJ, Saunders DM, Jones WR, Lyneham R, McMaster R (1982) The outcome of artificial donor insemination compared to the husband’s fertility status. Clin Reprod Fertil 1:295–299
Kovacs GT, Baker HW, Vaux HA (1983) Outcome of AID in initial and subsequent courses of treatment. Clin Reprod Fertil 2:295–298
Kovacs G, Baker G, Burger H, De Kretser D, Lording D, Lee J (1988) Artificial insemination with cryopreserved donor semen: a decade of experience. Br J Obstet Gynaecol 95:354–360
Kovacs GT, King C, Rogers P, Wood C, Baker HW, Yates C (1989) In vitro fertilization, a practical option after failed artificial insemination with donor semen. Reprod Fertil Dev 1:383–386
Kovacs GT, Mushin D, Kane H, Baker HW (1993) A controlled study of the psycho-social development of children conceived following insemination with donor semen. Hum Reprod 8:788–790
Kovacs GT, Breheny SA, Dear MJ (2003) Embryo donation at an Australian university in-vitro fertilisation clinic: issues and outcomes. Med J Aust 178:127–129
Kremer J (1965) A simple sperm penetration test. Int J Fertil 10:209–215
Lee J, Yap C (2003) Embryo donation: a review. Acta Obstet Gynecol Scand 82:991–996
Leeton J (1992) Clinical oocyte donation. In: Oocyte donation. Reprod Fertil Dev 4:601–604
Leeton J, Backwell J (1976) Artificial donor insemination. Aust N Z J Obstet Gynaecol 16:45–47
Leeton J, Selwood T, Trounson A, Wood C (1980) Artificial donor insemination frozen versus fresh semen. Aust N Z J Obstet Gynaecol 20:205–207
Lindheim SR, Sauer MV (1999) Embryo donation: a programmed approach. Fertil Steril 72:940–941
Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P (1984) The establishment viewpoint. Reprod and maintenance Biomed Online of pregnancy 7:139 — using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature 307:174–175
Lutjen PJ, Findlay JK, Trounson AO, Leeton JF, Chan LK (1986) Effect on plasma gonadotropins of cyclic steroid replacement in women with premature ovarian failure. J Clin Endocrinol Metab 62:419–423
Mahadevan M, Trounson A (1980) Cryopreservation of human semen. In: Wood C, Leeton J, Kovacs G (eds) Artificial insemination by donor. Brown, Prior and Anderson, Melbourne, pp 19–32
Mahadevan M, Trounson AO (1983) Effect of cryoprotective media and dilution methods on the preservation of human spermatozoa. Andrologia 15:355–366
Mahadevan M, Trounson AO (1984) Effect of cooling, freezing and thawing rates and storage conditions on preservation of human spermatozoa. Andrologia 16:52–60
Mahadevan MM, Trounson AO, Leeton JF (1983) Successful use of human semen cryobanking for in vitro fertilization. Fertil Steril 40:340–343
McGee G, Brakman SV, Gurmankin AD (2001) Gamete donation and anonymity: disclosure to children conceived with donor gametes should not be optional. Hum Reprod 16:2033–2036
McWhinnie A (1998) Ethical dilemmas in the use of donor gametes. Med Law 17:311–317
McWhinnie A (2001) Gamete donation and anonymity: should offspring from donated gametes continue to be denied knowledge of their origins and antecedents? Hum Reprod 16:807–817
Mochimaru F, Sato H, Kobayashi T, Iizuka R (1980) Physical and mental development of children born through AID. In: David G, Price W (eds) Human artificial insemination and sperm cyropreservation. Plenum, London, pp 277–282
Navot D, Laufer N, Kopolovic J et al (1986) Artificially induced endometrial cycles and establishment of pregnancies in the absence of the ovaries. N Engl J Med 314:806–811
Newton CR, McDermid A, Tekpetey F, Tummon IS (2003) Embryo donation: attitudes toward donation procedures and factors predicting willingness to donate. Hum Reprod 18:878–884
O’Connor A, Trounson A (1980) Assessment of artificial insemination success using life tables. In: Woog C, Leeton J, Kovacs G (eds) Artificial insemination by donor. Monash University Press, Melbourne, pp 33–37
Olatunbosun OA, Chizen DR, Pierson RA (1998) Screening of potential semen donors for sexual transmitted diseases. West Afr J Med 17:19–24
Palermo G, Joris H, Devroey P, Van Steirteghem AC (1992) Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 340:17–18
Patrizio P, Mastroianni AC, Mastroianni L (2001) Gamete donation and anonymity: disclosure to children conceived with donor gametes should be optional. Hum Reprod 16:2036–2038
Pennington GW, Naik S (1977) Donor insemination: report of a two-year study. Br Med J 1:1327–1330
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1–39
Randall GW, Gantt PA, Gantt D, Kirk MJ, Romines N (1996) Elevated serum progesterone values at the time of ovulation induction in luteal leuprolide acetate-down-regulated GIFT cycles are associated with decreased clinical pregnancy rates. J Assist Reprod Genet 13:459–463
Rosenwaks Z, Veeck L, Hung-Ching L (1986) Pregnancy following transfer of in vitro fertilised donated oocytes. Fertil Steril 45:417–420
Salamonsen L, Healy D (eds) (1992) Oocyte donation. Reprod Fertil Dev 4:1–148
Sathanandan M, Macnamee MC, Rainsbury P, Wick K, Brinsden P, Edwards RG (1991) Replacement of frozen-thawed embryos in artificial and natural cycles: a prospective semirandomized study. Hum Reprod 6:685–687
Serhal PF, Craft IL (1989) Oocyte donation in 61 patients. Lancet i:1185–1187
Shenfield F, Steele SJ (1997) What are the effects of anonymity and secrecy on the welfare of the child in gamete donation? Hum Reprod 12:392–395
Sherman J (1962) Preservation of bull and human spermatozoa by freezing in liquid nitrogen vapour. Nature 194:1291
Silber SJ, Devroey P, Tournaye H, Van Steirteghem AC (1995) Fertilizing capacity of epididymal and testicular sperm using intracytoplasmic sperm injection (ICSI). Reprod Fertil Dev 7:281–292; discussion 292–293
Soderstrom-Anttila V, Foudila T, Ripatti UR, Siegberg R (2001) Embryo donation: outcome and attitudes among embryo donors and recipients. Hum Reprod 16:1120–1128
Stenman UH, Alfthan H, Koskimies A, Seppala M, Pettersson K, Lovgren T (1985) Monitoring the LH surge by ultrarapid and highly sensitive immunofluorometric assay. Ann NY Acad Sci 442:544–550
Stewart GJ, Tyler JP, Cunningham AL, Barr JA, Driscoll GL, Gold J, Lamont BJ (1985) Transmission of human T-cell lymphotropic virus type III (HTLV-III) by artificial insemination by donor. Lancet 2:581–585
Thompson W, Boyle DD (1982) Counselling patients for artificial insemination and subsequent pregnancy. Clin Obstet Gynaecol 9:211–225
Toyooka Y, Tsunekawa N, Akasu R, Noce T (2003) Embryonic stem cells can form germ cells in vitro. Proc Natl Acad Sci USA 100:11457–11462
Trounson A (1992) The development of the technique of oocyte donation and hormonal replacement therapy: is oestrogen really necessary for the establishment and maintenance of pregnancy? Reprod Fertil Dev 4:671–679
Trounson AO (2001) The derivation and potential use of human embryonic stem cells. Reprod Fertil Dev 13:523–532
Trounson A (2005) Derivation characteristics and perspectives for mammalian pluripotential stem cells. Reprod Fertil Dev 17:135–41
Trounson A, Mohr L (1983) Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature 305:707–709
Trounson AO, Matthews CD, Kovacs GT, Spiers A, Steigrad SJ, Saunders DM, Jones WR, Fuller S (1981) Artificial insemination by frozen donor semen: results of multicentre Australian experience. Int J Androl 4:227–234
Trounson A, Leeton J, Besanko M, Wood C, Conti A (1983) Pregnancy established in an infertile patient after transfer of a donated embryo fertilised in vitro. Br Med J (Clin Res Ed) 286:835–838
Van Voorhis BJ, Grinstead DM, Sparks AE, Gerard JL, Weir RF (1999) Establishment of a successful donor embryo program: medical, ethical, and policy issues. Fertil Steril 71:604–608
Van Weert JM, Repping S, Van Voorhis BJ, van der Veen F, Bossuyt PM, Mol BW (2004) Performance of the postwash total motile sperm count as a predictor of pregnancy at the time of intrauterine insemination: a meta-analysis. Fertil Steril 82:612–620
Warner MP (1974) Artificial insemination. Review after thirty two years’ experience. N Y State J Med 74:2358–2361
Wortley PM, Hammett TA, Fleming PL (1998) Donor insemination and human immunodeficiency virus transmission. Obstet Gynecol 91:515–518
Bibliografia
Adler GJ (1997) Reconstruction of deformities resulting from penile enlargement surgery. J Urol 158:2153–2157
Adshead J, Khouhene B, Wood J, Rustin G (2001) Testicular implants and patient satisfaction: a questionnaire-based study of men after orchiectomy for testicular cancer. BJU Int 88:559–562
Ajamani ML, Jain SP, Saxena SK (1985) Anthropometric study of male external genitalia of 320 healthy Nigerian adults. Anthropol Anz 43:179–186
Austoni E, Guarnieri A, Gatti G (1999) Penile elongation and thickening — a myth? Is there a cosmetic medical indication? Andrologia 31:45–51
Chang TS, Hwang WY (1984) Forearm flap in one-stage reconstruction of the penis. Plast Reconstr Surg 74:251–258
Chen J, Gefen A, Greenstein A, Matzkin H, Elad D (2000) Predicting penile size during erection. Int J Impot Res 12:328–333
Donatucci CF, Ritter EF (1998) Management of the buried penis in adults. J Urol 159:420–424
Elder JS, Keating MA, Duckett JW (1989) Infant testicular prostheses. J Urol 141:1413–1415
Fossa SD, Aass N, Opjordsmoen S (1994) Assessment of quality of life in patients with prostate cancer. Semin Oncol 5:657–661
Hage JJ, Bloem JJ, Suliman HM (1993) Review of the literature on techniques for phalloplasty with emphasis on the applicability in femaletomale transsexuals. J Urol 150:1093–1098
Herndon CD, Casale AJ, Cain MP, Rink RC (2003) Long term outcome of the surgical treatment of concealed penis. J Urol 170:1695–1697
Incrocci L, Bosch JL, Slob AK (1999) Testicular prostheses: body image and sexual functioning. BJU Int 84:1043–1045
Jonker-Pool G, Van Basten JP, Hoekstra HJ, Van Driel MF, Sleijfer DTH (1995) Testicular cancer and sexual dysfunction. Int J Impot Res 7:23–24
Jordan GH (1999) Penile reconstruction, phallic construction and urethral reconstruction. Urol Clin North Am 26:1–19
Kim JJ, Kwack TI, Jeon BG, Cheon J, Moon DG (2003) Human glans penis augmentation using injectable hyaluronic acid gel. Int J Impot Res 15:439–443
Lowe MA, Chapman W, Berger RE (1991) Repair of traumatically amputated penis with return of erectile function. J Urol 145:1267–1270
Lynch MJ, Prior JP (1992) Testicular prostheses: the patient’s perception. Br J Urol 70:420–422
Mazza ON, Cheliz GMJ (2001) Glanuloplasty with scrotal flap for partial penectomy. J Urol 166:887–889
Mondaini N, Ponchietti R, Gontero P, Muir GH, Natali A, Di Loro F, Caldarera E, Biscioni S, Rizzo M (2002) Penile length is normal in most men seeking penile lengthening procedures. Int J Impot Res 14:283–286
Perovic SV, Djordjevic ML (2000) Penile lengthening. BJU Int 86:1028–1033
Ponchietti R, Mondaini N, Bonafè M, Di Loro F, Biscioni S, Masieri L (2001) Penile length and circumference: a study on 3,300 young Italian males. Eur Urol 39:183–186
Riba LW (1942) Subcapsular castration for carcinoma of prostate. J Urol 48:384–387
Schneider T, Sperling H, Lummen G, Syllwasschy J, Rubben H (2001) Does penile size in younger men cause problems in condom use? A prospective measurement of penile dimensions in 111 young and 32 older men. Urology 57:314–318
Schonfeld WA, Beebe GW (1942) Normal growth and variation in the male genitalia from birth to maturity. J Urol 48:759–777
Sengezer M, Ozturk S, Deveci M (2002) Accurate method for determining functional penile length in Turkish young men. Ann Plast Surg 48:381–385
Son H, Lee N, Huh JS, Kim SW, Paick JS (2003) Studies on self esteem of penile size in young Korean military men. Asian J Androl 5:185–189
Turek PJ Master VA and The Testicular Prosthesis Group (2004) Safety and effectiveness of a new saline filled testicular prosthesis. J Urol 172:1427–1430
Wessells H, Lue TF, Mc Aninch JW (1996) Complications of penile lengthening and augmentation seen at 1 referral center. J Urol 155:1617–1620
Bibliografia
Afaq F, Mukthar H (2002) Photochemoprevention by botanical antioxidants. Skin Pharmacol Appl Skin Physiol 15:297–306
Ahn MS, Catten M, Maas CS (2000) Temporal brow lift using botulinum toxin. A Plast Reconstr Surg 205:1129–1135
Alster AS (1998) Preoperative preparation for CO2 laser resurfacing. In: Coleman WP, Lawrence N (eds) Skin resurfacing. Williams and Wilkins, Baltimore, Md., pp 171–179
Ascher B, Klap P, Marion MH, Chanteloub F (1995) Botulinum toxin in the treatment of fronto-glabellar and periorbital wrinkles. An initial study. Ann Chir Plast Esthet 40:76
Becker-Wegerich P, Rauch L, Ruzicka T (2001) Botulinum toxin A in the therapy of mimic facial lines. Clin Exp Dermatol 26:619–630
Beckmann KVB, Ames BN (1997) Oxidative delay of DNA. J Biol Chem 272:19633
Binz T, Blasi J, Yamasaki S et al (1994) Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 269:1617
Black MM, Shuster S, Bottoms E (1970) Osteoporosis, skin collagen and androgen. Br Med J 4:773
Burton JL, Johnson C, Libman I (1972) Skin virilism in women with hirsutism. J Endocrinol 53:349
Carruthers JD, Carruthers JA (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18:17–21
Carruthers A, Carruthers J (1998a) Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg 24:1189–1194
Carruthers J, Carruthers A (1998b) The adjunctive usage of botulinum toxin. Dermatol Surg 24:1244–1247
Carruthers A, Carruthers J (1990) The treatment of glabellar furrows with botulinum A exotoxin. J Dermatol Surg Oncol 16:83
Carruthers A, Keine K, Carruthers J (1996) Cosmetic use of botulinum A exotoxin. J Am Acad Dermatol 34:788–797
Ditre CM, Griffin TD, Murphy GF, Sueki H, Telegan B, Johnson WC, Yu RJ, Van Scott EJ (1996) Effects of alpha-hydroxy acids on photoaged skin: a pilot clinical, histologic and ultrastructural study. J Am Acad Dermatol 34:187–195
Elmets CA, Singh D, Tubesing K, Matsui M, Kotiyar SK, Mukthar H (2001) Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol 44:425–432
Fisher GJ, Datta SC, Talwar HS (1996) Molecular basis of suninduced premature skin ageing and retinoid antagonism. Nature 379:335–339
Fluhr JW, Pelosi A, Lazzerini S, Dikstein S, Berardesca E (2001) Differences in corneocyte surface area in pre-and postmenopausal women. Skin Pharmacol Appl Skin Physiol Suppl 14:10–16
Forster JA, Wulc AE (1998) Cosmetic use of botulinum toxin. Semin Ophthalmol 13:142–148
Fritz K (2003) In: Krutmann J, Diepgen T (eds) Hautalterung. Springer, Berlin Heidelberg New York, p 86
Galinski FA, Pfeiffer HP, Trüper HG (1985) 1,4,5,6-Tetrahydro-2-methyl-4-pyrimidincarboxylic acid, a novel cyclic amino acid from halophilic bacteria of the genus Ectothiorhodospira. Eur J Biochem 149:135–139
Garcia A, Fulton J (1996) Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study. Dermatol Surg 22:39–43
Gerny H (2004) In: Worret WI, Gehring W (eds) Kosmetische Dermatologie. Springer, Berlin Heidelberg New York, pp 87–94
Grablowitz D (1999) Plastisch-ästhetische Indikationen im Gesichtsbereich. Urban and Vogel, Munich
Griffith CEM, Russman AN, Majmudar G, Singer RS, Hamilton TA, Voorhees JJ (1993) Restauration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med 329:530–535
Hambleton P (1992) Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 239:16
Harris B (1997) The aromatherapy database. Research into the physiological properties of essential oils and their components. St Helier, Jersey
Heckmann M, Rzany B (2002) Botulinumtoxin in der Dermatologie. Grundlagen und praktische Anwendung, Urban and Vogel, Munich
Hoppe U, Bergemann J, Diembeck W, Ennen J, Gohla S, Harris I, Jacob J, Kielholz J, Mei W, Pollet D, Schachtschabel D, Sauermann G, Schreiner V, Stab F, Steckel F (1999) Coenzyme Q10, a cutaneous antioxidant and energizer. BioFactors 9:371–378
Huang W, Rogachefsky AS, Foster JA (2000) Brow-lift with botulinum toxin. Dermatol Surg 26:55–60
Kao J, Garg A, Mao-Qiang M, Crumrine D, Ghadially R, Feingold KR, Elias PM (2001) Testosterone perturbs epidermal permeability barrier homeostasis. J Invest Dermatol 116:443–451
Kavallunas DR, Nacht S, Bogardus RE (1985) Men’s skin care needs. Cosmetics Toiletries 100:29–32
Kim SJ, Park JH, Carruthers A, Carruthers J (1998) Increased in vivo collagen synthesis and in vitro cell proliferative effect of glycolic acid. Dermatol Surg 24:1054
Klein AW, Wexler P, Carruthers A, Carruthers J (1997) Treatment of facial furrows and rhytides. Analysis and treatment of the aging face. Dermatol Clin 15:595–607
Klein M (2000) AHA’s provide novel approach to topical rejuvenation. Dermatology Times
Krutmann J, Hansen PM (2001) New developments in photoprotection of human skin. Skin Pharmacol Appl Skin Physiol 14:401–407
Nusgens BV, Humbert P, Rougier A, Colige AC, Haftek M, Lambert CA, Richard A, Creidi P, Laoiere CM (2001) Topically applied vitamin C enhances the mRNA level of collagen I and III, their processing enzymes and tissue inhibitors of matrix metalloproteinase 1 in the human dermis. J Invest Dermatol 116:853–859
Ricciarelli R, Maroni P, Ozer N, Zingg JM, Azzi A (1999) Agedependent increase of collagenase expression can be reduced by alpha-tocopherol via protein kinase C inhibition. Free Radic Biol Med 27:729–737
Rzarny B, Feller G (2000) Korrektur mimischer Falten: Botulinumtoxin A. Kosmetische Medizin 3:136–142
Shuster S, Black MM, Bottoms E (1970) Skin collagen and thickness in women with hirsuties. Br Med J 4:772
Shuster S, Black MM, McVitie E (1975) The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol 93:639–643
Simpson LL (1981) The origin, structure and pharmacological activity of botulinum toxin. Pharmacol Rev 33:155
Sommer B, Sattler G (1999) Botulinum A exotoxin, headache and acupuncture. Presentation at the 20th Congress of the International Society for Dermatologic Surgery, Athens, Greece
Sommer B, Sattler G (2000) Botulinumtoxin in der ästhetischen Medizin. Blackwell, Berlin
Tanaka H, Okada T, Konishi H, Tsuji T (1993) The effect of reactive oxygen species on the biosynthesis of collagen and glycosaminoglycans in cultured human dermal fibroblasts. Arch Dermatol Res 185:351–355
Vahlquist A, Lee JB, Michaelsson G, Rollman O (1982) Vitamin A in human skin: II Concentrations of carotene, retinol and dehydroretinol in various components of normal skin. J Invest Dermatol 79:94–97
Vochelle D (2004) The use of poly-L-lactic acid in the management of soft-tissue augmentation: a five-year experience. Semin Cutan Med Surg 23:223–226
Woerle B, Hanke CW, Sattler G (2004) Poly-L-lactic acid: a temporary filler for soft tissue augmentation. Drugs Dermatol 3:385–389
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
Evans, C.M. et al. (2010). Opzioni terapeutiche. In: Schill, WB., Comhaire, F., Hargreave, T.B., Lenzi, A., Isidori, A.M. (eds) Andrologia clinica. Springer, Milano. https://doi.org/10.1007/978-88-470-1487-9_21
Download citation
DOI: https://doi.org/10.1007/978-88-470-1487-9_21
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1486-2
Online ISBN: 978-88-470-1487-9
eBook Packages: MedicineMedicine (R0)